Page last updated: 2024-11-04

minoxidil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Minoxidil is a vasodilator medication primarily used to treat male pattern baldness and female pattern hair loss. It is also used to treat high blood pressure. Minoxidil was initially synthesized in the 1950s as a potential treatment for hypertension, but it was found to have unintended effects on hair growth. Its exact mechanism of action is not fully understood, but it is believed to work by promoting blood flow to the scalp, stimulating hair follicles, and prolonging the anagen (growth) phase of the hair cycle. Minoxidil is available over-the-counter (OTC) in topical formulations for hair loss, and by prescription for both oral and topical use. It is typically applied to the scalp twice daily. Minoxidil is generally considered safe for most people when used as directed. Common side effects include scalp irritation, itching, and unwanted hair growth in other areas of the body. In rare cases, more serious side effects can occur, such as chest pain, swelling in the hands or feet, and rapid weight gain. Minoxidil is often studied to investigate its potential for treating various conditions, including hair loss, alopecia areata, and even certain types of cancer. Its unique ability to stimulate hair growth and its potential to impact cellular processes makes it a subject of ongoing research.'

Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4201
CHEMBL ID802
CHEMBL ID609587
CHEMBL ID1372483
CHEBI ID6942
CHEBI ID92128
SCHEMBL ID232565
SCHEMBL ID29698
MeSH IDM0013916

Synonyms (254)

Synonym
CBIOL_001798
minodyl
tricoxidil
6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine
theroxidil
lonolox
alostil
minoxidilum [inn-latin]
minossidile [italian]
2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide
prexidil
u-10,858
alopexil
6-(1-piperidinyl)-2,4-pyrimidinediamine 3-oxide
MLS001077294
HMS3266O06
REGID855572
AB00052047-08
AB00513797-02
BRD-K14888893-001-02-3
BRD-K06902185-001-05-2
MLS000028566 ,
smr000058963
DIVK1C_000160
KBIO1_000160
loniten
u-10858
rogaine
riup
regaine
minoximen
tm-160
neoxidil
SGCUT00112
EU-0100786
minoxidil, >=99% (tlc)
SPECTRUM_000969
IDI1_033855
PRESTWICK_521
minoxidil
38304-91-5
NCGC00015673-02
BIO1_000084
BIO1_000573
BIO2_000585
NCGC00024666-01
cas-38304-91-5
BIO2_000105
tocris-0583
NCGC00015673-01
lopac-m-4145
BIO1_001062
PRESTWICK3_000020
BSPBIO_002037
BSPBIO_001385
NCGC00179672-01
BPBIO1_000065
LOPAC0_000786
IDI1_000160
BCBCMAP01_000193
PRESTWICK2_000020
BSPBIO_000059
normoxidil
minoxidilum
CHEBI:6942 ,
apo-gain
AB00513797
TO_000070
smr000326812
DB00350
2,4-diamino-6-piperidinopyrimidine 3-oxide
MLS000859953
minoxidil (jan/usp/inn)
rogaine (tn)
riup (tn)
loniten (tn)
D00418
6-piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
NCGC00024666-06
NCGC00024666-04
NCGC00024666-07
NCGC00024666-03
KBIO3_000209
KBIO2_001449
KBIOSS_001449
KBIO2_006585
KBIO3_001537
KBIOGR_000105
KBIO2_004017
KBIO2_002673
KBIO2_005241
KBIOGR_000585
KBIOSS_000105
KBIO2_000105
KBIO3_000210
SPBIO_001006
SPECTRUM3_000509
SPECTRUM4_000063
NINDS_000160
SPBIO_001980
PRESTWICK1_000020
PRESTWICK0_000020
SPECTRUM2_001053
SPECTRUM1500415
SPECTRUM5_001299
SMP1_000192
3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine
NCGC00024666-02
NCGC00024666-05
NCGC00018278-01
NCGC00024666-08
6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide
NCGC00015673-04
HMS2091F20
HMS2089L08
AC-5271
HMS1989F07
M 4145 ,
NCGC00015673-11
nsc-757106
pierminox
CHEMBL802
mintop
HMS1791F07
HMS500H22
HMS1361F07
CHEMBL609587
m1389 ,
2,6-diamino-4-piperidinopyrimidine 1-oxide
HMS1568C21
HMS1920P03
3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
NCGC00015673-08
cas_4201
nsc_4201
bdbm81463
NCGC00018278-04
NCGC00018278-03
NCGC00018278-02
HMS2095C21
HMS3259P21
HMS3262M14
2-azanylidene-3-oxidanyl-6-piperidin-1-yl-pyrimidin-4-amine
3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine
A824098
nsc757106
pharmakon1600-01500415
dtxsid9040685 ,
tox21_110193
dtxcid7020685
avacor and mintop
AKOS015920078
HMS2233E04
HMS2235N21
CCG-40112
NCGC00015673-07
NCGC00015673-03
NCGC00015673-10
NCGC00015673-06
NCGC00015673-09
NCGC00015673-05
BCP9000929
5965120sh1 ,
BCPP000162
LP00786
S1383
AKOS016339636
HMS3371E15
HMS3372M19
2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate
gtpl4254
FT-0620793
SCHEMBL232565
minoxidil [usp monograph]
minoxidil [hsdb]
minoxidil [inn]
minoxidil [usan]
minoxidil [usp-rs]
minoxidil [vandf]
minoxidil [mart.]
minoxidil [ep monograph]
minoxidil [jan]
minoxidil [mi]
2,4-diamino-6-piperidinopyrimidine 3-oxide.
minoxidil [orange book]
minoxidil [who-dd]
minoxidil [inci]
CCG-220020
HY-B0112
CS-1867
ZFMITUMMTDLWHR-UHFFFAOYSA-N
NC00686
SCHEMBL29698
NCGC00015673-13
tox21_110193_1
KS-5164
tox21_500786
NCGC00261471-01
ZIMGGGWCDYVHOY-UHFFFAOYSA-N
6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidino-pyrimidine
6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide
Q-201408
6-(1-piperidinyl)-2,4-pyrimidinediamine3-oxide
HB1094
CHEMBL1372483
HMS3402F07
OPERA_ID_1150
AB00052047_10
AB00052047_09
mfcd00063409
women''''s rogaine
men''''s rogaine
minoxidil extra strength
rogaine extra strength
regaine for women
regaine for men
bdbm50237593
STL453211
u10858
GS-3605
SR-01000075331-1
sr-01000075331
CHEBI:92128
minoxidil, united states pharmacopeia (usp) reference standard
SR-05000001479-1
sr-05000001479
SR-05000001479-2
minoxidil, european pharmacopoeia (ep) reference standard
minoxidil for system suitability, european pharmacopoeia (ep) reference standard
SR-01000075331-5
SR-01000075331-3
SBI-0050764.P004
HMS3712C21
minoxidil, british pharmacopoeia (bp) reference standard
Z1541638524
6-amino-2-imino-4-(piperidin-1-yl)-1,2-dihydropyrimidin-1-ol
Q424165
BD164673
HMS3675G16
minoxidil,(s)
pyrimidin-1(2h)-ol
6-amino-2-imino-4-(piperidin-1-yl)
BCP01409
HMS3411G16
BRD-K06902185-001-10-2
EN300-121204
SDCCGSBI-0050764.P005
NCGC00015673-20
O10620
H10337
minoxidil (u-10858)
PD003089
SY075383
mfcd00072128

Research Excerpts

Overview

Minoxidil is a vasodilator drug generally employed for the treatment of various forms of alopecia. It is an antihypertensive that works by directly dilating peripheral vessels. Minxidil has proven to be a successful and well-tolerated alternative for patients with hair loss.

ExcerptReferenceRelevance
"Minoxidil, which is a pyrimidine N-oxide, can be reduced to its corresponding pyrimidine via a redox reaction."( A new mechanism for resonance Rayleigh scattering detection of minoxidil based on catalytic oxidation of silver nanoparticles.
Chompoosor, A; Praditweangkum, W; Teerasong, S, 2022
)
1.68
"Minoxidil is a commonly used drug by many people for the treatment of hair fall with or without doctor advice. "( Pleural Effusion Induced by Systemic Consumption of Topical Minoxidil: A Rare Case Report.
Krishna Sasanka, KSBS; Kumar, KSP; Kuotsu, R; Tanguturi Yella, SH; Tanguturi Yella, SS; Thangaraju, P, 2023
)
2.6
"Minoxidil is a vasodilator drug generally employed for the treatment of various forms of alopecia. "( Extemporaneous Topical Minoxidil Solutions for the Treatment of Alopecia: Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base.
Denora, N; Dibenedetto, MT; Fontana, S; Franco, M; la Forgia, FM; Lopalco, A; Lopedota, AA; Spennacchio, A,
)
1.88
"Minoxidil is a common therapeutic option for AGA patients because of its availability."( A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia.
Asim, M; Ouellette, S; Rao, B; Shah, A; Shah, R; Sharif, S, 2023
)
1.85
"Oral minoxidil is a safe and successful treatment of androgenic alopecia and AA. "( Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review.
Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020
)
1.43
"Minoxidil is a strong arterial vasodilator, first introduced as an antihypertensive medication. "( Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?
de La-Rocque, M; de Oliveira, DS; Lemes, LR; Melo, DF; Ramos, PM; Zompero, C, 2020
)
2.34
"Oral minoxidil was found to be an effective and well-tolerated treatment alternative for healthy patients having difficulty with topical formulations."( Oral minoxidil treatment for hair loss: A review of efficacy and safety.
Randolph, M; Tosti, A, 2021
)
1.65
"Minoxidil is an antihypertensive that works by directly dilating peripheral vessels. "( Signs of early cardiac tamponade induced by Minoxidil.
Ali, A; Oye, M, 2021
)
2.33
"Oral minoxidil has proven to be a successful and well-tolerated alternative for patients with hair loss, including those with poor adherence to other therapies."( Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Fabbrocini, G; Ocampo-Candiani, J; Ocampo-Garza, SS; Ruggiero, A; Villani, A, 2021
)
1.43
"Minoxidil is a widely used over-the-counter topical treatment for hair loss. "( SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth.
Daruwalla, S; Dhurat, R; Goren, A; Kovacevic, M; McCoy, J; Pai, S; Shapiro, J; Sinclair, R; Vano-Galvan, S, 2022
)
2.58
"Minoxidil is a pro-drug converted into its active form, minoxidil sulfate, by the sulfotransferase enzymes in the outer root sheath of hair follicles."( Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients.
Dhurat, R; Goldust, M; Goren, A; Kovacevic, M; Lotti, T; Lukinovic Skudar, V; McCoy, J; Shapiro, J; Sharma, A; Sinclair, R; Situm, M, 2018
)
1.47
"Minoxidil is an FDA-approved anti-hypertensive agent that inhibits LH that reduces fibrosis."( Lysyl Hydroxylase Inhibition by Minoxidil Blocks Collagen Deposition and Prevents Pulmonary Fibrosis via TGF-β₁/Smad3 Signaling Pathway.
Duan, L; Fang, H; Guo, B; Liu, W; Rao, S; Shao, S; Zhang, X, 2018
)
1.49
"Minoxidil is a drug used to stimulate hair growth and to slow balding. "( Stability of minoxidil in Espumil foam base.
Geiger, CM; Sorenson, B; Whaley, PA,
)
1.94
"Minoxidil is a potent antihypertensive used as an adjunctive agent in refractory hypertension. "( Minoxidil-associated anorexia in an infant with refractory hypertension.
Attarian, SJ; Cole, FS; Vesoulis, ZA; Zeller, B, 2014
)
3.29
"Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. "( 5% Minoxidil: treatment for female pattern hair loss.
Foley, KA; Gupta, AK,
)
2.2
"Minoxidil is a pro-drug converted to its active form, minoxidil sulfate, by sulfotransferase enzymes in the outer root sheath of hair."( Doppler laser imaging predicts response to topical minoxidil in the treatment of female pattern hair loss.
Bolanca, Z; Goren, A; Kovacevic, M; McCoy, J; Situm, M; Stanimirovic, A,
)
1.1
"Minoxidil (Mx) is a conventional drug for treating androgenetic alopecia, preventing hair loss, and promoting hair growth. "( Effectiveness of a Layer-by-Layer Microbubbles-Based Delivery System for Applying Minoxidil to Enhance Hair Growth.
Chen, HK; Liao, AH; Lin, YC; Lu, YJ; Sytwu, HK; Wang, CH, 2016
)
2.1
"Minoxidil is a direct-acting peripheral vasodilator for the treatment of symptomatic hypertension, or refractory hypertension associated with target organ damage, that is not manageable with a diuretic and two other antihypertensive drugs. "( Fatal toxic epidermal necrolysis associated with minoxidil.
Chahine-Chakhtoura, C; Karaoui, LR, 2009
)
2.05
"Minoxidil is a strong vasodilator used first in the 1970s for severe hypertension."( [Minoxidil intoxication, the pharmacological agent of a hair lotion].
Aprahamian, A; Chéron, G; Escoda, S; Merckx, A; Patteau, G, 2011
)
2
"Minoxidil (Rogaine®) is a direct vasodilator that can cause significant toxicity when ingested. "( Refractory hypotension due to Rogaine® (minoxidil) ingestion managed with midodrine.
Aaronson, P; Garrard, A; Sollee, D; Wood, A, 2011
)
2.08
"Minoxidil is a potassium channel opener, causing hyperpolarization of cell membranes and it is also a vasodilator, it is speculated that, by widening blood vessels and opening potassium channels, it allows more oxygen, blood and nutrients to the follicle."( Minoxidil use in dermatology, side effects and recent patents.
Calvieri, S; Cantisani, C; Iorio, A; Melis, L; Rossi, A; Scali, E, 2012
)
2.54
"Minoxidil is a K(+) channel opener able to cause relaxation of vascular smooth muscles and modify cell growth and cell fate or migration. "( Topically applied minoxidil may cause fetal malformation: a case report.
Caldarella, A; Caramelli, L; Di Lollo, S; Moroni, F; Smorlesi, C, 2003
)
2.1
"Minoxidil is a direct vasodilator introduced in the early 1970s for the treatment of hypertension. "( Minoxidil: an underused vasodilator for resistant or severe hypertension.
Sica, DA, 2004
)
3.21
"Minoxidil is a potent, long-acting, orally effective vasodilator that recently became available for general use in the United States. "( Evaluation of a new antihypertensive agent. Minoxidil.
Kosman, ME, 1980
)
1.97
"Minoxidil is an orally active vasodilator for treatment of severe hypertension. "( Minoxidil.
Linas, SL; Nies, AS, 1981
)
3.15
"Minoxidil was found to be an effective antihypertensive drug in these patients with refractory hypertension."( Treatment of refractory hypertension with minoxidil.
Beroniade, V; Hamet, P; Kuchel, O; Larochelle, P, 1980
)
1.25
"Minoxidil is a potent oral vasodilator acting on the arteriolar side of the circulation. "( Pharmacology and pharmacokinetics of minoxidil.
Affrime, MB; Lowenthal, DT, 1980
)
1.98
"Minoxidil is a valuable antihypertensive drug in children but should be used with caution."( Severe hypertension in children with renal disease: treatment with minoxidil.
Kaiser, BA; Maltz, HE; Potter, DE; Puri, HC, 1983
)
1.22
"Minoxidil is an orally effective vasodilator that selectively relaxes peripheral arteriolar smooth muscle, Reflex tachycardia, renin stimulation, and sodium retention occur when minoxidil is used and so it requires the concomitant use of a diuretic and a sympathoplegic agent, usually a beta blocker."( Evaluation of minoxidil.
Love, DW; Miller, DD, 1980
)
1.34
"Minoxidil appears to be an effective arterial dilating agent in patients with heart failure and resembles hydralazine in its actions."( Effects of minoxidil on hemodynamics in patients with congestive heart failure.
Cohn, JN; Franciosa, JA, 1981
)
1.37
"Minoxidil is a potent antihypertensive drug widely used in severe arterial hypertension and in that refractory to treatment. "( Minoxidil in severe and moderately severe hypertension, in association with methyldopa and chlortalidone.
Cotorruelo, JG; Flórez, J; Llamazares, C, 1982
)
3.15
"Minoxidil is a new potent antihypertensive vasodilator. "( Minoxidil and pericardial effusion: an idiosyncratic reaction.
Reichgott, MJ, 1981
)
3.15
"Minoxidil is an extremely potent hypotensive drug. "( Minoxidil and labetalol: very effective antihypertensive combination.
Bett, N; Boyle, P; Craswell, P; Whiting, G, 1980
)
3.15
"Minoxidil appears to be a potent stimulator for elastin expression in skin fibroblasts."( Stimulation of elastin expression by minoxidil in chick skin fibroblasts.
Hayashi, A; Nishikawa, T; Suzuki, T; Tajima, S, 1995
)
1.29
"Minoxidil is an inhibitor of lysyl hydroxylase, an enzyme involved in collagen production, and decreases collagen production in vitro. "( Effect of lysyl hydroxylase inhibitor, minoxidil, on ultrastructure and behavior of cultured rabbit subconjunctival fibroblasts.
Hashizume, N; Kobata, S; Okada, Y; Ooshima, A; Saika, S; Tanaka, S; Yamanaka, O, 1995
)
2
"Minoxidil is a potent antihypertensive agent used in the treatment of resistant hypertension. "( Minoxidil, hypercoagulability and thromboembolic disease of the lung.
Edmunds, M; Holton, J; Keohane, SG; Swales, JD, 1996
)
3.18
"Minoxidil is an antihypertensive agent and hair growth promoter that is metabolized by sulfation to the active compound, minoxidil sulfate. "( Sulfation of minoxidil by multiple human cytosolic sulfotransferases.
Anderson, RJ; Clemens, DL; Kudlacek, PE, 1998
)
2.11
"Minoxidil is a potent arterial vasodilator used in the treatment of hypertension. "( Overdose of Rogaine Extra Strength for Men topical minoxidil preparation.
Epstein, SK; Farrell, SE, 1999
)
2
"Minoxidil is a direct vasodilator that has been in use for over two decades. "( Direct vasodilators and their role in hypertension management: minoxidil.
Gehr, TW; Sica, DA,
)
1.81
"Minoxidil is an inhibitor of lysyl hydroxylase, an enzyme involved in procollagen hydroxylation."( Effect of minoxidil on rabbit lens epithelial cell behavior in vitro and in situ.
Ishida, I; Ohnishi, Y; Saika, S, 2001
)
1.43
"Minoxidil seems to be a safe and potent antihypertensive drug for long-term use in severe arterial hypertension, but it cannot be recommended for routine treatment."( Long-term experiences with minoxidil in combination treatment of severe arterial hypertension.
Lederballe Pedersen, O, 1977
)
1.28
"Minoxidil is an effective oral antihypertensive agent for treatment of severe hypertension in pediatric patients."( Minoxidil therapy in children with severe hypertension.
Bernstein, BH; Ettenger, RB; Fine, RN; Hanson, V; Malekzadeh, MH; Pennisi, AJ; Singsen, BH; Takahashi, M; Uittenbogaart, C, 1977
)
2.42
"Minoxidil appears to be a useful antihypertensive drug for treating patients who do not respond adequately to therapy with diuretic and beta adrenergic blocking agents."( Effect of minoxidil on blood pressure and hemodynamics in severe hypertension.
Bryan, RK; Hoobler, SW; Purdy, JM; Rosenzweig, J; Weller, JM, 1977
)
1.38
"Minoxidil is a remarkably potent hypotensive with relatively few side effects and seems particularly advantageous in patients with chronic renal failure."( Long-term treatment of severe hypertension with minoxidil.
Caron, C; Montambault, P; Nawar, T; Nolin, L; Plante, GE, 1977
)
1.23
"Minoxidil is an effective antihypertensive agent."( The effect of minoxidil on blood pressure and plasma renin activity in patients with essential and renal hypertension.
Werning, C, 1976
)
1.34
"Minoxidil is a new, effective, investigational antihypertensive drug. "( Minoxidil-induced hypertrichosis: treatment with calcium thioglycolate depilatory.
Aeling, JL; Ball, J; Earhart, RN; Nuss, DD, 1977
)
3.14
"Minoxidil is a potent orally administered vasodilator under investigation for use in severe hypertension. "( The outpatient treatment of refractory hypertension with minoxidil.
Ball, JH; Kleiner, JP; Nelson, WP; Norton, JD, 1977
)
1.94
"Minoxidil is a potent vasodilator useful in treating severe hypertension. "( Topical treatment with minoxidil 2% and smoking intolerance.
Ingber, A; Trattner, A, 1992
)
2.04
"Minoxidil sulfate is an antihypertensive agent belonging to the new class of vasodilators, the "K+ channel openers." The present study was undertaken to characterize the effects of minoxidil sulfate on ionic and secretory events in rat pancreatic islets. "( Ionic and secretory response of pancreatic islet cells to minoxidil sulfate.
Antoine, MH; Herchuelz, A; Hermann, M; Lebrun, P, 1991
)
1.97
"Minoxidil is a relatively safe treatment for extensive alopecia areata and may be effective in the treatment of some cases of recalcitrant disease."( Extensive alopecia areata. Results of treatment with 3% topical minoxidil.
Bergfeld, WF; Ranchoff, RE; Steck, WD; Subichin, SJ,
)
1.09
"Minoxidil is an antihypertensive vasodilator with no known capability of inducing human cardiovascular pathology; however, the compound does cause a late, canine-specific lesion of the right atrium and acute right atrial and ventricular papillary muscle changes. "( Review of cardiovascular findings in humans treated with minoxidil.
Sobota, JT, 1989
)
1.96
"Minoxidil is a potent antihypertensive which is reserved for severe cases. "( [Massive pericardial effusion following minoxidil].
Brook, JG; Levy, Y; Moskowitz, M, 1989
)
1.99
"Minoxidil is a potent peripheral vasodilator used to treat patients with severe hypertension that is unresponsive to other medications. "( Severe hypertrichosis of the external ear canal during minoxidil therapy.
Berktold, RE; Konior, RJ; Toriumi, DM, 1988
)
1.96
"Minoxidil is a potent antihypertensive vasodilator. "( Minoxidil does not possess androgenic activity.
Broulik, PD; Horký, K, 1988
)
3.16

Effects

Minoxidil (MXD) has an inhibitory effect on lysyl hydroxylase, which influences the quality of extracellular matrix crosslinking. It could therefore be used to reduce the stiffness and to improve the flexibility of the tissue.

Oral minoxidil has proven to be a successful and well-tolerated alternative for patients with hair loss, including those with poor adherence to other therapies. Little is known about its pharmacological activity or about the identity of its target cells in hair follicles.

ExcerptReferenceRelevance
"Minoxidil (MXD) has an inhibitory effect on lysyl hydroxylase, which influences the quality of extracellular matrix crosslinking, and could therefore be used to reduce the stiffness and to improve the flexibility of the tissue."( Minoxidil decreases collagen I deposition and tissue-like contraction in clubfoot-derived cells: a way to improve conservative treatment of relapsed clubfoot?
Bacakova, L; Doubkova, M; Eckhardt, A; Knitlova, J; Musilkova, J; Novotny, T; Ostadal, M; Plencner, M; Vondrasek, D, 2021
)
2.79
"Minoxidil has a particularly annoying side effect of hypertrichosis that may limit its use, particularly among women."( Minoxidil: an underused vasodilator for resistant or severe hypertension.
Sica, DA, 2004
)
2.49
"Minoxidil has a direct dilator effect on the systemic arterial smooth muscle. "( Minoxidil reduces pulmonary vascular resistance in dogs and cattle.
Chidsey, CA; Grover, RF; Weil, JV; Weir, EK, 1976
)
3.14
"Minoxidil 5% solution has been shown to have superior efficacy to minoxidil 2% solution, it is unknown whether concentrations of minoxidil > 5% provide additional clinical benefit."( Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit?
Goldust, M; Kianfar, N; Patil, A; Rudnicka, L; Sinclair, R; Singh, S; Waśkiel-Burnat, A, 2022
)
1.81
"Minoxidil has come a long-way finding its use from topical formulations to systemic at lower dose in different alopecia."( Comprehensive review of oral minoxidil in alopecia.
Modha, JD; Pathania, YS, 2022
)
1.73
"Oral minoxidil has been used in various non-scarring and scarring alopecia at a lower dosage with less side effects and with promising results. "( Comprehensive review of oral minoxidil in alopecia.
Modha, JD; Pathania, YS, 2022
)
1.53
"Minoxidil has been used as an effective and cost-efficient topical treatment for androgenic alopecia. "( Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging.
Elnawawy, T; Makhlouf, A, 2023
)
2.65
"Minoxidil 2% and 5% have been FDA approved for treatment of this condition."( Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.
Alarawi, A; Bessar, H; Ghonemy, S, 2021
)
1.61
"Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia. "( Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
Jain, K; Pereira, A; Venkatesh, R; Yadav, NK, 2020
)
3.44
"Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA). "( Efficacy and safety of oral minoxidil in female androgenetic alopecia.
Annunziata, MC; Cantelli, M; Fabbrocini, G; Nappa, P; Patrì, A; Vastarella, M, 2020
)
1.37
"Minoxidil (MXD) has an inhibitory effect on lysyl hydroxylase, which influences the quality of extracellular matrix crosslinking, and could therefore be used to reduce the stiffness and to improve the flexibility of the tissue."( Minoxidil decreases collagen I deposition and tissue-like contraction in clubfoot-derived cells: a way to improve conservative treatment of relapsed clubfoot?
Bacakova, L; Doubkova, M; Eckhardt, A; Knitlova, J; Musilkova, J; Novotny, T; Ostadal, M; Plencner, M; Vondrasek, D, 2021
)
2.79
"Oral minoxidil has proven to be a successful and well-tolerated alternative for patients with hair loss, including those with poor adherence to other therapies."( Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Fabbrocini, G; Ocampo-Candiani, J; Ocampo-Garza, SS; Ruggiero, A; Villani, A, 2021
)
1.43
"Minoxidil has been approved for the treatment of hair loss, however its mechanism of action is still not fully clarified."( An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia.
Aliper, A; Consolo, M; Cooper, KD; McCormick, TS; Mirmirani, P; Ozerov, IV; Pappas, A; Schastnaya, J; Stamatas, GN; Wu, J; Zhavoronkov, A, 2017
)
1.38
"Minoxidil has never been considered by radiotherapists."( Targeting solid tumours with potassium channel activators. A return to fundamentals?
Trechot, P,
)
0.85
"Minoxidil has been implicated in pleuropericardial effusions in patients with chronic kidney disease."( Minoxidil-associated exudative pleural effusion.
Ansari, M; Chemitiganti, R; Shakil, J; Siddiqui, A, 2010
)
2.52
"Minoxidil has been widely used to treat androgenetic alopecia, but little is known about its pharmacological activity or about the identity of its target cells in hair follicles. "( Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle.
Cho, KH; Chung, JH; Eun, HC; Han, JH; Kim, KH; Kwon, OS, 2004
)
2.17
"Minoxidil has a particularly annoying side effect of hypertrichosis that may limit its use, particularly among women."( Minoxidil: an underused vasodilator for resistant or severe hypertension.
Sica, DA, 2004
)
2.49
"Minoxidil has been shown to stimulate hair growth and these studies were undertaken to determine whether the drug had a direct effect on keratinocytes. "( Effect of minoxidil on cultured keratinocytes.
Baden, HP; Kubilus, J, 1983
)
2.11
"Minoxidil (U-10,858) has been shown in several controlled and blind studies and numerous uncontrolled studies to be a potent peripheral vasodilator for use in the management of sustained, severe, accelerating or malignant hypertension and moderate hypertension inadequately controlled by conventional therapy. "( Minoxidil.
Canaday, B, 1980
)
3.15
"Minoxidil has been proposed as a potential topical inhibitor of wound contraction and proliferative scarring. "( Minoxidil and wound contraction.
Carney, G; Hill, DP; Ko, F; Polo, M; Robson, MC; Wright, TE, 1997
)
3.18
"Minoxidil has several other side effects that may limit its use, including hypertrichosis, aggravation of myocardial ischemia and/or left ventricular hypertrophy, and (infrequently) pericardial effusions."( Direct vasodilators and their role in hypertension management: minoxidil.
Gehr, TW; Sica, DA,
)
1.09
"Minoxidil has been reported to stimulate the production of vascular endothelial growth factor, a possible promoter of hair growth, in cultured dermal papilla cells."( Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil.
Arase, S; Fukui, K; Li, M; Marubayashi, A; Nakaya, Y, 2001
)
2.47
"Minoxidil has been administered to 16 patients with severe hypertension and renal failure. "( Minoxidil in severe hypertension.
Mäkelä, M; Oka, M, 1978
)
3.14
"Minoxidil has a direct dilator effect on the systemic arterial smooth muscle. "( Minoxidil reduces pulmonary vascular resistance in dogs and cattle.
Chidsey, CA; Grover, RF; Weil, JV; Weir, EK, 1976
)
3.14
"Minoxidil has been studied extensively and has been shown to improve balding at the vertex of the scalp, particularly in young men who have only begun to lose hair."( Hair loss. What causes it and what can be done about it.
Burke, KE, 1989
)
1
"Minoxidil has generated new interest in hair-loss research."( Topical minoxidil therapy for hair regrowth.
Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1987
)
1.43

Actions

Minoxidil was found to inhibit the proliferation of smooth muscle cells in the proliferating phase, but not in the quiescent phase. Minoxidill promotes the survival of human DPCs by activating both ERK and Akt and by preventing cell death by increasing Bcl-2/Bax.

ExcerptReferenceRelevance
"Minoxidil directly promotes hair growth via the stimulation of dermal papilla (DP) and epithelial cells. "( Minoxidil Promotes Hair Growth through Stimulation of Growth Factor Release from Adipose-Derived Stem Cells.
Choi, N; Shin, S; Song, SU; Sung, JH, 2018
)
3.37
"Minoxidil led to a an increase of normal hair shaft without any side effects in all the patients."( Monilethrix treated with minoxidil.
Carlesimo, M; Fortuna, MC; Greco, P; Iorio, A; Mari, E; Palese, E; Rossi, A; Scali, E,
)
1.16
"Minoxidil may also cause prolongation of anagen and increases hair follicle size."( Minoxidil: mechanisms of action on hair growth.
Messenger, AG; Rundegren, J, 2004
)
2.49
"Minoxidil promotes the survival of human DPCs by activating both ERK and Akt and by preventing cell death by increasing the ratio of Bcl-2/Bax. "( Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle.
Cho, KH; Chung, JH; Eun, HC; Han, JH; Kim, KH; Kwon, OS, 2004
)
2.17
"Minoxidil did not inhibit the contractions at both examined concentrations except for a very small effect at 1 Hz."( Inhibitory effects of different ATP-sensitive potassium channel openers on electrically generated and carbachol-induced contractions of porcine and human detrusor muscle.
Badawi, JK; Bross, S; Ding, A, 2008
)
1.07
"Minoxidil treatment may cause an early initiation of anagen, but both the minoxidil-treated skin and the vehicle-treated skin entered telogen at the same time."( Use of gamma-glutamyl transpeptidase activity as a marker of hair cycle and anagen induction in mouse hair follicles.
Buhl, AE; Johnson, GA; Kawabe, TT; Kubicek, MF, 1994
)
1.01
"Minoxidil was found to inhibit the proliferation of smooth muscle cells in the proliferating phase, but not in the quiescent phase. "( Minoxidil stimulates elastin expression in aortic smooth muscle cells.
Hayashi, A; Murad, S; Nishikawa, T; Pinnell, SR; Suzuki, T; Tajima, S; Wachi, H, 1994
)
3.17
"Minoxidil failed to inhibit the response of isolated vessels to potassium chloride."( Interactions of minoxidil with vasoconstrictive agents in isolated rat tail artery.
Buckzko, W; Godlewski, G; Wasiński, R; Wróbel, B,
)
1.2

Treatment

Minoxidil treatment was associated with a significant reduction in blood pressure from 162.4±15.1/83.7 mm Hg to 135.8±12.2/72.8mm Hg (P<.0001) Minoxidill treatment resulted in a prolonged reduction in mean, systolic and diastolic blood pressure (up to 24%).

ExcerptReferenceRelevance
"%5 minoxidil alone in the treatment of the androgenetic alopecia."( Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.
Faghihi, G; Hoseyni, MS; Iraji, F; Jelvan, M; Saber, M; Siadat, AH, 2022
)
1.55
"(2), Minoxidil (5%) treated group (3), Methylsulfonylmethane (10%) treated group (4), Methylsulfonylmethane plus Minoxidil treated group."( EVALUATION OF THE EFFECT OF TOPICALLY APPLIED METHYLSULFONYLMETHANE AND THEIR COMBINATION WITH MINOXIDIL SOLUTION FOR IMPROVEMENT OF HAIR GROWTH IN MALE MICE.
Gany, SN; Hadi, NR; Hummadi, AA, 2022
)
1.4
"Minoxidil treatment resulted in a 0.22 fold change for 5α-R2 (p < 0.0001)."( Minoxidil Acts as an Antiandrogen: A Study of 5α-reductase Type 2 Gene Expression in a Human Keratinocyte Cell Line.
Pekmezci, E; Türkoğlu, M, 2017
)
2.62
"Minoxidil treatment was associated with a significant reduction in blood pressure from 162.4±15.1/83.2±12.7 mm Hg to 135.8±12.2/72.8±6.9 mm Hg (P<.0001)."( Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis.
Benck, U; Birck, R; Göttmann, U; Krämer, BK; Lammert, A; Matenaer, M; Mundt, HM, 2016
)
2.6
"Minoxidil treatment resulted in a prolonged reduction in mean, systolic and diastolic blood pressure (up to 24%)."( Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog.
Patel, B; Sullivan, AT; Taylor, GL,
)
0.85
"Minoxidil treatment lowered blood pressure from 178/112 +/- 8/5 mm Hg (means +/- SEM) to 14/95 +/- 6/3 mm Hg."( Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses.
Baer, L; Radichevich, I; Williams, GS, 1980
)
1.24
"Minoxidil-treated pigs had tachycardia and hypotension and were killed 24 hr after the second dose."( Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine.
Ferrans, VJ; Herman, EH; Van Vleet, JF, 1984
)
1.25
"In minoxidil treated patients, the effusions resolved spontaneously in 4 (3 remaining on treatment), required pericardiocentesis (3), or pericardiectomy (1), and persisted in 4 (3 remaining on treatment)."( Pericardial effusion associated with minoxidil therapy in dialyzed patients.
Gelfand, MC; Gottlieb, MJ; Horton, JD; Lazarus, JM; Schreiner, GE; Winchester, JF; Zarate, A, 1980
)
1.05
"The minoxidil treated cultures had a higher desmosome density compared to parallel control cultures and they expressed the suprabasal keratins 1 and 10 (indicating progress in differentiation) earlier and to a larger extent than the controls."( Effect of minoxidil on the mobility and differentiation of cultivated human keratinocytes.
Bereiter-Hahn, J; Bernd, A; Breuer, M; Dold, K; Görmar, F; Holzmann, H; Jackel, C; Ramirez-Bosca, A; Theilig, C, 1994
)
1.17
"Minoxidil treatment may cause an early initiation of anagen, but both the minoxidil-treated skin and the vehicle-treated skin entered telogen at the same time."( Use of gamma-glutamyl transpeptidase activity as a marker of hair cycle and anagen induction in mouse hair follicles.
Buhl, AE; Johnson, GA; Kawabe, TT; Kubicek, MF, 1994
)
1.01
"In minoxidil-treated rats, the extent of reversal in LV mass and dilation by the two blockers was similar to "spontaneous regression" after discontinuation of minoxidil treatment."( Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats.
Leenen, FH; Ruzicka, M; Yuan, B, 1994
)
0.8
"Both minoxidil-SEPA treatments produced significantly greater cumulative hair weight over the entire 16-week study compared to either of the Rogaine TS treatments."( The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque.
Brunden, MN; Diani, AR; Shull, KL; Zaya, MJ, 1995
)
0.97
"Minoxidil treatment (120 and 200 mg/l) significantly increased left ventricular dry weight normalized for body weight by 19 +/- 4 and 24 +/- 4%, respectively."( Minoxidil-induced cardiac hypertrophy in guinea pigs.
Borgdorff, P; Stienen, GJ; van der Velden, J, 1999
)
2.47
"Minoxidil treatment (1.5 mg/kg) resulted in a steady decline in MAP values of 16.3 to 18.6% relative to basal control levels at 35 to 60 min following minoxidil injection."( Induction of rat hepatic aryl sulfotransferase (SULT1A1) gene expression by triamcinolone acetonide: impact on minoxidil-mediated hypotension.
Duanmu, Z; Dunbar, J; Falany, CN; Runge-Morris, M, 2000
)
1.24
"Minoxidil treatment was more effective in the absence of other signs of hyperandrogenism, hyperseborrhoea, and menstrual cycle modifications when the BMI was low, and when nothing argued in favour of biochemical hyperandrogenism. "( Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.
Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002
)
2.15
"Minoxidil-treated patients with hypertension previously refractory to conventional therapy had slightly lower pulmonary vascular resistance than other hypertensive subjects."( Increased pulmonary vascular resistance with systemic hypertension. Effect of minoxidil and other antihypertensive agents.
Atkins, JM; Mitchell, HC; Pettinger, WA, 1977
)
1.21
"Minoxidil treatment for 8 weeks in both strains resulted in a decrease in mean arterial pressure and increases in ventricular weight to body weight ratios, plasma IR-ANP concentrations (in WKY from 133 +/- 20 to 281 +/- 34 pg ml-1, P less than 0.01; in SHR from 184 +/- 38 to 339 +/- 61 pg ml-1, P less than 0.05), and in ventricular IR-ANP contents (in WKY: 53%; in SHR: 41%)."( Release of atrial natriuretic peptide from rat myocardium in vitro: effect of minoxidil-induced hypertrophy.
Kinnunen, P; Leppäluoto, J; Ruskoaho, H; Taskinen, T, 1990
)
1.23
"Minoxidil treatment causes an appreciable decrease in hydroxylysine with compensatory increases in lysine content, and the delayed sodium dodecyl sulfate-polyacrylamide gel electrophoretic mobility of the overmodified collagen chains becomes normal."( Decreased thermal denaturation temperature of osteogenesis imperfecta mutant collagen is independent of post-translational overmodifications of lysine and hydroxylysine.
de Wet, W; Hollister, DW; Rao, VH; Steinmann, B, 1989
)
1
"Minoxidil treatment increased left ventricular weight and spermidine (83 and 61% in WKY and SHR rats, respectively) and spermine (44 and 28%) content."( Cardiac polyamine metabolism in spontaneously hypertensive rats: effect of antihypertensive treatment.
Raunio, H; Ruskoaho, H, 1986
)
0.99
"Minoxidil-treated patients responded better than placebo-treated patients."( Topical minoxidil in extensive alopecia areata, including 3-year follow-up.
Price, VH, 1987
)
1.43
"Treatment with minoxidil, an inhibitor of hypoxia-induced sarcoma metastasis, abrogated cell migration and matrix remodeling in the hypoxic gradient."( Intratumoral oxygen gradients mediate sarcoma cell invasion.
Eisinger-Mathason, TS; Gerecht, S; Lewis, DM; Pak, K; Park, KM; Simon, MC; Tang, V; Xu, Y, 2016
)
0.77
"The treatment with minoxidil induced myocardial necrosis, coronary arteriopathy and degeneration of renal tubules in animals treated with 150 mg/kg or 200 mg/kg."( Cardiovascular toxicity of minoxidil in the marmoset.
Bonnet, P; Daguès, N; Eder, V; Hanton, G; Rochefort, GY; Sobry, C, 2008
)
0.96
"Pretreatment with minoxidil significantly enhanced the recovery of myocardial contraction during reperfusion after ischemia."( Effects of minoxidil on ischemia-induced mechanical and metabolic dysfunction in dog myocardium.
Ichihara, K; Ichinosawa, K; Kaneta, S; Kano, S; Satoh, K; Yamamoto, A, 2002
)
1.03
"Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss."( Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
Blume-Peytavi, U; Ellwanger, U; Garcia Bartels, N; Hoffmann, R; Krisp, A; Kunte, C, 2007
)
0.95
"Treatment with minoxidil was continued for four months; tolerance to the drugs was not observed."( Minoxidil in severe and moderately severe hypertension, in association with methyldopa and chlortalidone.
Cotorruelo, JG; Flórez, J; Llamazares, C, 1982
)
2.05

Toxicity

The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects. Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxIDil in treating patchy AA.

ExcerptReferenceRelevance
" However, the safety of no systemic adverse effect and the potential of inhibiting progressive shedding of hair were valuable as a topical drug."( Safety and efficacy of 2% topical minoxidil in the management of male pattern baldness in Chinese.
Chan, HL; Chen, MJ; Chen, SY; Kuan, YZ; Wang, CN, 1990
)
0.56
" Captopril was initiated in those patients in whom previous antihypertensive agents either failed to control high blood pressure or produced adverse reactions."( Acute titration and chronic follow-up with captopril in hypertension. A one-year safety profile on combination therapy with captopril and a diuretic.
Hunter, KW; Mahapatra, D; Mahapatra, RK; Yaden, S, 1986
)
0.27
" In conclusion, the cardiovascular toxicity of MNX in dogs is not caused by a direct toxic effect of MNX on the heart but apparently is related to the exaggerated pharmacologic/profound hemodynamic effects it elicits in the dog."( The pharmacologic basis of the cardiovascular toxicity of minoxidil in the dog.
DuCharme, DW; Higgins, MJ; Mesfin, GM; Robinson, FG; Zhong, WZ,
)
0.38
"TMS is a safe and effective treatment for AGA."( Safety of topical minoxidil solution: a one-year, prospective, observational study.
Shapiro, J,
)
0.47
" LD50 was found to be 1690 mg/kg."( Effect of potassium channel modulators on toxicity of Cleistanthus collinus.
Anand, KN; Ernest, K; Jeyaseelan, L; Jose, VM; Kuruvilla, A, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" It was however discovered to have the important side-effect of increasing growth or darkening of fine body hairs; this led to the development of a topical formulation as a 2% concentration solution for the treatment of female androgenic alopecia or 5% for treating male androgenic alopecia."( Minoxidil use in dermatology, side effects and recent patents.
Calvieri, S; Cantisani, C; Iorio, A; Melis, L; Rossi, A; Scali, E, 2012
)
1.82
" MFX may be a safe and effective treatment option."( Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Tanglertsampan, C, 2012
)
0.68
" This is a significant limitation because sustained changes in blood pressure are often accompanied by changes in heart rate and together can lead to cardiac hypertrophy and myocardial degeneration in animals, and major adverse cardiovascular events (MACE) in humans."( Natriuretic Peptides as Cardiovascular Safety Biomarkers in Rats: Comparison With Blood Pressure, Heart Rate, and Heart Weight.
Engle, SK; Watson, DE, 2016
)
0.43
"This study confirmed that minoxidil 5% topical foam is a safe and effective treatment for MPHL."( Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.
Firooz, A; Halavati, N; Hasanzadeh, H; Nasrollahi, SA; Saberi, M, 2016
)
1.03
" However, little is known about the differences in adverse effects between these two drugs."( Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
Li, Q; Wu, M; Yu, Q, 2016
)
0.43
" However, there have been occasional reports of adverse events that were caused mostly by propylene glycol sensitivity."( A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia.
Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017
)
0.7
" Clinical outcomes and adverse events were recorded at 8, 16, and 24 weeks."( A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia.
Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017
)
0.7
"Both formulations were found to be effective and safe in the treatment of male AGA."( A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia.
Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017
)
0.7
"The panoply of products used by hair care professionals to wash, dye, shape and beautify hair is not entirely free from adverse events."( [Adverse effects of hair care in users].
Herman, A; Lachapelle, JM; Tennstedt, D,
)
0.13
" However, the concern regarding adverse effects of finasteride use has been rising."( A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018
)
0.69
" Changes in plasma dihydrotestosterone levels and adverse events were recorded."( A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018
)
0.69
" There were also no systemic adverse events reported by patients in both groups."( A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018
)
0.69
" Adverse events were evaluated."( A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019
)
0.71
" There was no significant difference between the combined group and minoxidil- or finasteride-only groups in the number of patients with moderate and mild improvements, hair density change, or adverse events."( The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Chen, B; Chen, L; Wang, H; Wang, L; Zhang, J, 2020
)
1.03
"In recent years, oral minoxidil at low dose has been proposed as a safe alternative."( Oral minoxidil treatment for hair loss: A review of efficacy and safety.
Randolph, M; Tosti, A, 2021
)
1.45
" to analyze available data of patients treated with OM, focusing on safety and adverse effects."( Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.
Fernandez-Nieto, D; Jaen-Olasolo, P; Jimenez-Cauhe, J; Moreno-Arrones, OM; Ortega-Quijano, D; Rodrigues-Barata, R; Saceda-Corralo, D; Vaño-Galvan, S, 2020
)
0.87
" The main side effect was pain due to PRP injection, which disappeared after ending the treatment and only one article reported more serious side effects."( Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability.
Behrangi, E; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2021
)
0.62
"The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects."( Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
Bhoyrul, B; Hermosa-Gelbard, A; Jaén-Olasolo, P; Jerjen, R; Jimenez-Cauhe, J; John, JM; Koh, WL; Lo-Sicco, K; Moreno-Arrones, ÓM; Piraccini, BM; Pirmez, R; Poa, JE; Rodrigues-Barata, R; Rudnicka, L; Saceda-Corralo, D; Salas-Callo, CI; Shapiro, J; Sinclair, R; Starace, M; Tosti, A; Trindade de Carvalho, L; Vañó-Galván, S; Vincenzi, C; Waskiel-Burnat, A; Yin, L; Zamorano, JL, 2021
)
1.18
" The most frequent adverse effect was hypertrichosis (15."( Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
Bhoyrul, B; Hermosa-Gelbard, A; Jaén-Olasolo, P; Jerjen, R; Jimenez-Cauhe, J; John, JM; Koh, WL; Lo-Sicco, K; Moreno-Arrones, ÓM; Piraccini, BM; Pirmez, R; Poa, JE; Rodrigues-Barata, R; Rudnicka, L; Saceda-Corralo, D; Salas-Callo, CI; Shapiro, J; Sinclair, R; Starace, M; Tosti, A; Trindade de Carvalho, L; Vañó-Galván, S; Vincenzi, C; Waskiel-Burnat, A; Yin, L; Zamorano, JL, 2021
)
0.93
"To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients."( Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Ablon, G; Fischer, DL; Gade, A; Han, H; Nestor, MS, 2021
)
0.62
" Topical finasteride, while not FDA-approved, lacks the systemic adverse effects associated with oral finasteride."( Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?
Gupta, AK; Talukder, M, 2022
)
0.72
"To review whether topical finasteride is a safe and effective treatment for male and female pattern hair loss."( Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?
Gupta, AK; Talukder, M, 2022
)
0.72
" Adverse events are of particular concern in this population."( Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.
John, JM; Sinclair, RD, 2023
)
1.33
" Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects."( Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial.
Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022
)
1.18
" The few and widely used monotherapies approved by the US Food and Drug Administration, such as minoxidil or finasteride, are not efficacious in all people and cause adverse events that prevent patient compliance."( Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia.
Abidi, Z; Arruda, S; Rapaport, J; Sadgrove, NJ; Sadick, N; Swearingen, A, 2023
)
1.13
" No scarring nor serious adverse events were reported in any of the studies."( Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis.
Abdi, P; Anthony, MR; Awad, C; Farkouh, C; Kenny, B; Maibach, HI; Ogunyemi, B, 2023
)
1.15

Pharmacokinetics

Minoxidil should be used as in other populations: begin with a modest dose, and adjust the dose based on clinical response. It was found that the hypotensive effect of minxidil declined linearly with time at a rate consistent with an average effective biologic half-life of about one day.

ExcerptReferenceRelevance
" Pharmacokinetic variables have been determined that allow: (1) derivation of the loading dose necessary to achieve rapid control of blood pressure with propranolol hydrochloride, guanethidine, minoxidil and clonidine hydrochloride; (2) reduced frequency of dosing with methyldopa, hydralazine hydrochloride, prazosin hydrochloride, propranolol and clonidine; and (3) alteration of propranolol and hydralazine dosage based on physiologic factors (e."( Using pharmacokinetics in drug therapy. V: Contributions to developing dosage regimens for antihypertensive drugs.
Schumacher, GE, 1979
)
0.45
" In a few studies, investigators have correlated, under controlled conditions and in a small number of patients, the pharmacokinetic variables needed to individualize minoxidil and clonidine dosage regimens with clinical responses (mean arterial blood pressure)."( Using pharmacokinetics in drug therapy. IV: Consideration in applying pharmacokinetic and pharmacodynamic estimates to antihypertensive dosage regimens.
Schumacher, GE; Wilson, AL, 1979
)
0.45
" It was found that the hypotensive effect of minoxidil declined linearly with time at a rate consistent with an average effective biologic half-life of about one day."( Pharmacodynamics of minoxidil as a guide for individualizing dosage regimens in hypertension.
Gibaldi, M; McNay, JL; O'Malley, K; Shen, D, 1975
)
0.84
" Minoxidil concentrations determined by RIA were highly correlated with concentrations determined by HPLC; only the HPLC data was used in the pharmacokinetic analyses."( The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers.
Andreadis, NA; Fleishaker, JC; Welshman, IR; Wright, CE, 1989
)
1.44
" A pharmacokinetic study in a hypertensive volunteer receiving two different oral doses of minoxidil (1."( Minoxidil analysis in human plasma using high-performance liquid chromatography with electrochemical detection. Application to pharmacokinetic studies.
Abernethy, DR; Carrum, G; Sadhukhan, M; Wright, CE, 1986
)
1.93
" The half-life is approximately 3 hr, regardless of whether the dose is given singly or on a multiple-dose basis."( Pharmacology and pharmacokinetics of minoxidil.
Affrime, MB; Lowenthal, DT, 1980
)
0.53
" No differences were observed in lorazepam pharmacokinetic parameters."( Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998
)
0.62
" In the absence of multiple-dose minoxidil pharmacodynamic studies in this population, minoxidil should be used as in other populations: begin with a modest dose, and adjust the dose based on clinical response."( Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998
)
0.9

Compound-Compound Interactions

Microneedling combined with 5% minoxidil can improve AGA. The underlying mechanism may involve activation of the Wnt/β-catenin signaling pathway.

ExcerptReferenceRelevance
"5 mg/day, alone or in combination with topical 2% minoxidil, for 20 weeks to determine the effects on scalp hair growth in balding adult male stumptail macaque monkeys."( Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque.
Brunden, MN; Buhl, AE; Diani, AR; Johnson, GA; Kubicek, MF; Mulholland, MJ; Schostarez, HJ; Shull, KL, 1992
)
0.74
"Minoxidil in combination with a beta-adrenergic blocker and a diuretic was used in 12 male hypertensive patients who did not respond to or who developed unpleasant side-effects from the available medications."( Minoxidil in combination with a beta-adrenergic blocker and a diuretic as an antihypertensive in patients refractory to available medications.
Rawat, R; Seedat, YK, 1981
)
3.15
"14 patients with refractory hypertension did not respond either to captopril, an angiotensin II converting enzyme inhibitor, combined with a diuretic, a beta-blocker and hydralazine or minoxidil, a potent vasodilator, but they did respond to the combination of captopril, minoxidil, furosemide and a beta-blocker."( Captopril combined with minoxidil, beta-blocker and furosemide in the treatment of refractory hypertension.
Rawat, R; Seedat, YK, 1983
)
0.76
"Anticonvulsant effect of cytoskeletal depolymerizing drugs in combination with potassium channel (KATP) opener and adenylate cyclase activator was evaluated in animal models of epilepsy."( Anticonvulsant effect of cytoskeletal depolymerizers in combination with potassium channel opener and adenylate cyclase activator; a causative link with nerve growth factor?
Jose, VM; Tyagi, MG, 2001
)
0.31
" We evaluated the effect of minoxidil combined with ATRA on hair growth in vitro."( Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro.
Chung, JH; Eun, HC; Han, JH; Kim, KH; Kwon, OS; Lee, SR; Oh, YJ; Pyo, HK, 2007
)
0.96
" The safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with the botanical hair solution for 12 weeks in 54 subjects was evaluated in a multicenter, single-arm, open-label study."( Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia.
McMichael, A; Meckfessel, MH; Pham, H; von Grote, E, 2016
)
0.99
" The safety and efficacy of a twice-daily regimen of 5% minoxidil foam used in combination with a novel botanical hair solution was evaluated in a 12-week, multicenter, single-arm, open label study in 56 subjects with mild to moderate AGA."( Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia.
Keaney, TC; Meckfessel, MH; Pham, H; von Grote, E, 2016
)
0.99
" To compare the efficacy and safety of fractional Er:Glass laser used in combination with topical 5% minoxidil versus 5% minoxidil alone for the treatment of male AGA, 30 men with AGA were randomized to 24 weeks of split-scalp treatment using fractional Er:Glass laser and 5% minoxidil on one side (combined therapy) or 5% minoxidil alone on the other side (monotherapy)."( A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019
)
0.92
"To evaluate the efficacy of microneedling combined with 5% minoxidil in Chinese male AGA patients and to explore the underlying mechanisms."( Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.
Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022
)
1.2
"Microneedling combined with 5% minoxidil can improve AGA, and the underlying mechanism may involve activation of the Wnt/β-catenin signaling pathway."( Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.
Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022
)
1.24
"The goal was to explore the efficacy and side effects of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male patients with early stage of androgenetic alopecia (AGA)."( Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia.
Liu, C; Wu, W; Zhang, Y; Zhao, H, 2022
)
1.16
"To evaluate the efficacy and safety of 2% minoxidil combined with microneedling in the treatment of female pattern hair loss."( Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population.
Hu, R; Sheng, Y; Wang, W; Yang, Q; Zeng, Y; Zhang, Y; Zhao, J, 2022
)
1.24
"Microneedling combined with minoxidil had better efficacy for female pattern hair loss during the treatment period and follow-up."( Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population.
Hu, R; Sheng, Y; Wang, W; Yang, Q; Zeng, Y; Zhang, Y; Zhao, J, 2022
)
1.27
" However, the efficacy of PRPF combined with minoxidil treatment remains unknown."( Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial.
Chen, J; Dai, D; Guan, Q; Hu, Z; Le, D; Liu, S; Liu, W; Miao, Y; Qu, Q; Wu, S, 2023
)
1.39
"In this prospective, randomized controlled trial, 75 patients with AGA were randomly divided into three groups and were administered the following treatments: Group 1, direct intradermal PRPF injection; Group 2, topical minoxidil 5% twice daily; and Group 3, PRPF injection combined with minoxidil."( Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial.
Chen, J; Dai, D; Guan, Q; Hu, Z; Le, D; Liu, S; Liu, W; Miao, Y; Qu, Q; Wu, S, 2023
)
1.32
"To evaluate the efficacy and safety of PRP prepared by automatic blood cell separator combined with topical 5% minoxidil therapy in male AGA."( Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia.
Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023
)
1.34
" Patients were randomly divided into two treatment arms: (group A) PRP prepared by automatic blood cell separator combined with topical 5% minoxidil group; (group B) PRP prepared by automatic blood cell separator combined with a topical placebo group."( Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia.
Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023
)
1.33
"We hereby conclude that the injections of PRP prepared by an automated method are effective and safe in the treatment of mild-to-moderate male AGA patients, and its combination with topical 5% minoxidil therapy was superior to PRP monotherapy with better clinical efficacy and higher patient satisfaction."( Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia.
Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023
)
1.31

Bioavailability

Minoxidil (MXD) is commonly used topically to treat alopecia, but its low absorption rate limits widespread use. Niosomes have been reported as a possible approach to improve the low skin penetration and bioavailability characteristics shown by conventional topical vehicle.

ExcerptReferenceRelevance
" Our object was to assess long-term clinical efficacy, kinetics (acute and chronic), and bioavailability of minoxidil in chronic renal insufficiency."( Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function.
Affrime, M; Busby, P; Kim, KE; Lowenthal, DT; Martinez, EW; Mutterperl, R; Onesti, G; Shirk, J; Swartz, C, 1978
)
0.71
" Following oral administration of a single dose, the drug was rapidly and well absorbed and rapidly eliminated by each species as judged by plasma levels and urinary excretion of unchanged drug and total drug-related materials."( Metabolism of minoxidil, a new hypotensive agent I: absorption, distribution, and excretion following administration to rats, dogs, and monkeys.
Harpootlian, H; Hsi, RS; Judy, RW; Thomas, RC, 1975
)
0.62
"The cutaneous bioavailability of topical 2% minoxidil solution was verified in live hairless mice."( Drug and vehicle deposition from topical applications: localization of minoxidil within skin strata of the hairless mouse.
Ferry, JJ; Flynn, GL; Tsai, JC; Weiner, N, 1994
)
0.78
"The bioavailability of drugs administered topically or orally depends on their metabolism by epithelial enzymes such as the cytosolic sulfotransferases (SULT)."( Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells.
Dooley, TP; Haldeman-Cahill, R; Joiner, J; Wilborn, TW, 2000
)
0.31
"Niosomes have been reported as a possible approach to improve the low skin penetration and bioavailability characteristics shown by conventional topical vehicle for minoxidil."( Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.
Balakrishnan, P; Choi, HG; Kim, DD; Kim, JO; Kim, JS; Lee, WM; Lee, WS; Oh, DH; Shanmugam, S; Woo, JS; Yong, CS; Yoo, BK, 2009
)
0.82
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Measurement of drug concentration in biological matrices (such as serum, plasma, blood, urine, and saliva) is important to determine Bioavailability (BA) and/or Bioequivalence (BE) of a drug product which are required during the drug product development and approval process to support applications for new active substances (INDs, NDAs) and generic (ANDAs) drug products to make critical decisions on safety and efficacy."( Estimation of minoxidil in human plasma using UHPLC-MS/MS and its application in pharmacokinetic study.
Nalini, CN; Poorna Basuri, P; Vijayakumar, R, 2022
)
1.08
" Minoxidil (MXD) is commonly used topically to treat alopecia, but its low absorption rate limits widespread use."( Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model.
An, BS; Jeong, JS; Kim, DS; Kim, MJ; Kim, SY; Lee, S; Seong, KY; Yang, SY, 2022
)
3.07
"Topical treatments to modulate hair growth are generally limited by low drug bioavailability due to poor skin permeability."( Modulation of hair growth by topical drug delivery enhanced by STAR particles.
Prausnitz, MR; Woo, MR, 2023
)
0.91

Dosage Studied

A dose-response effect has previously been demonstrated in topical minoxidil treatment of alopecia areata. The duration of treatment ranged from 1 to 30 months. Average captopril dosage was 265 mg/d (150-300 mg) and average minoxIDil dosage was 19.5mg/d.

ExcerptRelevanceReference
"Pharmacokinetic methods that have been used to improve antihypertensive drug therapy, including antihypertensive dosage regimens, are reviewed."( Using pharmacokinetics in drug therapy. V: Contributions to developing dosage regimens for antihypertensive drugs.
Schumacher, GE, 1979
)
0.26
" Further expansion of plasma volume was prevented by furosemide, individual dosage requirement ranging from 40 to 500 mg/day, irrespective of the renal function."( [Effects of minoxidil on blood pressure and plasma volume in refractory hypertension (author's transl)].
Alhenc-Gelas, F; Ménard, J; Morgado Vital, A; Plouin, PF, 1979
)
0.64
"A theory explaining the pharmacokinetics of drugs with direct and rapidly reversible pharmacologic effects is reviewed, and the application of this theory to individualizing dosage regimens for antihypertensive drugs is discussed."( Using pharmacokinetics in drug therapy. IV: Consideration in applying pharmacokinetic and pharmacodynamic estimates to antihypertensive dosage regimens.
Schumacher, GE; Wilson, AL, 1979
)
0.26
"7 years) with severe essential hypertension (n = 21) and renovascular hypertension (n = 1) were treated with a mean daily dosage of 16."( [Minoxidil in treatment resistant hypertension].
Furrer, J; Nussberger, J; Reuteler, H; Siegenthaler, W; Studer, A; Tenschert, W; Vetter, W, 1979
)
1.17
" The average maximum dosage of minoxidil was 27."( The effect of minoxidil on blood pressure and plasma renin activity in patients with essential and renal hypertension.
Werning, C, 1976
)
0.9
" We have reported previously that when the peak lowering of MAP is linearly regressed against log dose, both the dose-response slope (M) and threshold dose (Dt) are positively correlated with the MAP bi of individual patients."( Pharmacodynamics of minoxidil as a guide for individualizing dosage regimens in hypertension.
Gibaldi, M; McNay, JL; O'Malley, K; Shen, D, 1975
)
0.58
" Following an initial dose of 5 mg, subsequent dosage increments were administered every 6 hr until a fall in blood pressure was observed."( A method for achieving blood pressure control expeditiously with oral minoxidil.
McNay, JL; O'Malley, K, 1975
)
0.49
" Sections of skin from C3H and CF1 mice which were topically dosed with minoxidil (in vivo) showed no minoxidil-immunoreactivity."( Immunohistochemical and autoradiographic findings suggest that minoxidil is not localized in specific cells of vibrissa, pelage, or scalp follicles.
Buhl, AE; Diani, AR; Johnson, GA; Kawabe, TT; Knight, KA; Sawada, GA; Walker, CJ; Zelei, BV, 1990
)
0.75
" Dose-response studies showed that minoxidil sulfate is 14 times more potent than minoxidil in stimulating cysteine incorporation in cultured follicles."( Minoxidil sulfate is the active metabolite that stimulates hair follicles.
Baker, CA; Buhl, AE; Johnson, GA; Waldon, DJ, 1990
)
2
" Cumulative urinary excretion profiles within steady-state, 12-h dosing intervals were well described by straight lines for all treatments, indicating that systemic minoxidil elimination was rate controlled by constant, zero-order percutaneous drug absorption."( Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution.
Ferry, JJ; Shepard, JH; Szpunar, GJ, 1990
)
0.7
" The spectrophotometric methods were applied to the quality control of commercial minoxidil dosage forms and the results were comparable with those obtained by a reference HPLC procedure."( Determination of minoxidil in pharmaceutical formulations by difference spectrophotometry and liquid chromatography (HPLC).
Bonazzi, D; Cavrini, V; Di Pietra, AM; Gatti, R, 1990
)
0.84
" In a dose-response study with minoxidil, the maximal effect of the drug was seen at doses from 6 to 12 micrograms/ml; however, activity could be detected at doses below 1 microgram/ml."( Effect of minoxidil on pre- and postconfluent keratinocytes.
Baden, HP; Kubilus, J; Kvedar, JC, 1987
)
0.96
" Also, the presence of excipients of the tablet dosage form did not interfere with the extraction process of minoxidil."( Determination of the optimum solvent system for extraction of minoxidil from a tablet dosage form.
Babar, A; Mahzouf, SZ; Plakogiannis, FM, 1989
)
0.73
" The initial dose probably saturates the skin for a period of time longer than the dosing intervals examined."( Absorption of minoxidil after topical application: effect of frequency and site of application.
Della-Coletta, AA; Eller, MG; Szpunar, GJ, 1989
)
0.64
" Thus, the disposition of minoxidil is significantly delayed and dosage adjustment may be necessary in patients with renal insufficiency."( Disposition of minoxidil in patients with various degrees of renal function.
Andreadis, NA; Fleishaker, JC; Halstenson, CE; Matzke, GR; Opsahl, JA; Sobieraj, J; Wright, CE, 1989
)
0.93
" Initial titration dosage was decided on the basis of initial blood pressure recordings."( Acute titration and chronic follow-up with captopril in hypertension. A one-year safety profile on combination therapy with captopril and a diuretic.
Hunter, KW; Mahapatra, D; Mahapatra, RK; Yaden, S, 1986
)
0.27
" Average captopril dosage was 265 mg/d (150-300 mg), average minoxidil dosage was 19."( [Comparison of the effect of captopril and minoxidil on left ventricular mass. Results of a 6-month comparative double-blind test].
Chatellier, G; Corvol, P; Dufloux, MA; Ménard, D; Ménard, J; Plouin, PF; Prasquier, R, 1987
)
0.78
" When minoxidil is discontinued, diuretic dosage requires re-evaluation and possible tapering to prevent volume depletion."( Orthostatic hypotension occurring after discontinuation of long-term minoxidil therapy.
Noel, HC, 1988
)
0.99
" In the first study, 101 patients on a fixed combination of atenolol 100mg and chlorthalidone 25mg who required additional or 'third line' therapy for proper control, were randomised to either felodipine or hydralazine and the dosage was increased if the supine diastolic blood pressure was greater than 90mm Hg."( The use of felodipine in the treatment of severe hypertension.
Muir, AL; Wathen, CG, 1987
)
0.27
"Fifty-eight men with Hamilton scale type III vertex or type IV male pattern baldness were studied to determine the dose-response activity of low concentrations of topical minoxidil in promoting hair growth."( Dose-response study of topical minoxidil in male pattern alopecia.
Jondreau, L; Kassimir, JJ; Reed, ML; Shupack, JL; Thirumoorthy, T, 1987
)
0.75
" A dose-response effect was demonstrated when 48 patients treated with topical 1% minoxidil were compared with 47 patients treated with topical 5% minoxidil."( Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata.
Fiedler-Weiss, VC, 1987
)
0.93
"A dose-response effect has previously been demonstrated in topical minoxidil treatment of alopecia areata."( Evaluation of oral minoxidil in the treatment of alopecia areata.
Buys, CM; Fiedler-Weiss, VC; Rumsfield, J; Wendrow, A; West, DP, 1987
)
0.84
" After 3 and 6 months of maintenance therapy, blood pressures were measured 24 hours after the previous day's dosing to evaluate the persistence of the antihypertensive effect."( The management of severe hypertension with minoxidil in a once-a-day treatment regimen.
Bayley, A; Fraser, HS; Hassell, TA; Nicholson, GD, 1985
)
0.53
" The results strongly suggest a dose-response effect for topical minoxidil treatment of alopecia areata and the importance of exploring modifications in dosing and delivery systems to enhance therapeutic efficacy."( Topical minoxidil dose-response effect in alopecia areata.
Buys, CM; Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1986
)
0.94
" Clonidine followed by prazosin was added to their regimen on an outpatient basis to establish the dose-response for BP and catecholamines."( Clonidine and prazosin effects in hypernoradrenergic vasodilator-treated and beta-blocker-treated patients.
Mitchell, HC; Pettinger, WA, 1981
)
0.26
" The duration of treatment ranged from 1 to 30 months, and the minoxidil dosage ranged from 5 to 60 mg/dry electrocardiographic changes characterized by T-wave inversion after starting minoxidil."( Treatment of refractory hypertension with minoxidil.
Beroniade, V; Hamet, P; Kuchel, O; Larochelle, P, 1980
)
0.77
" All patients had diastolic blood pressures above 95 mm Hg after therapy with thiazide diuretics for 2 weeks and were randomly assigned to treatment schedules which added minoxidil and propranolol in dosage ratios of 1:2, 1:4, and 1:8."( Minoxidil in the management of moderate hypertension.
Alleyne, GA; Nicholson, GD; Valdes, G; Westerman, RL, 1980
)
1.9
" Vasodilators are active within a fairly wide dosage range, making individualized dosages requisite."( [Antihypertensive vasodilators].
Plouin, PF, 1983
)
0.27
" Full PH dose-response curves for standard antihypertensive drugs were explored and were compared to their hypotensive dose-response curves."( Antihypertensive drugs: their postural hypotensive effect and their blood pressure lowering activity in conscious normotensive rats.
Carver, LA; Lee, CH; Strosberg, AM, 1983
)
0.27
" The acute blood-pressure-lowering effect of nifedipine in the Dahl salt-sensitive rat was characterized by a rapid onset of action, the minimal effective oral dosage (0."( Factors involved in the antihypertensive action of calcium antagonists.
Garthoff, B; Kazda, S; Knorr, A; Thomas, G,
)
0.13
" A booster dosage of 5 to 20 mg of minoxidil was given at four hours if the diastolic BP exceeded 100 mm Hg."( Rapid control of severe hypertension with minoxidil.
Alpert, MA; Bauer, JH, 1982
)
0.81
"The chemistry, pharmacokinetics, mechanism of action, clinical studies, adverse effects, toxicology, indications, contraindications, drug interactions, and dosing of minoxidil, a recently approved antihypertensive agent, are reviewed."( Evaluation of minoxidil.
Love, DW; Miller, DD, 1980
)
0.82
" These data, which can be modeled similarly to plasma concentration data, will determine the optimal dosing interval."( Dose response studies with vasodilator antihypertensive drugs.
McNay, JL, 1982
)
0.26
" However, worsening edema developed in all patients, requiring increased diuretic dosage and close supervision."( Effects of acute and chronic minoxidil administration on rest and exercise hemodynamics and clinical status in patients with severe, chronic heart failure.
Nathan, M; Rubin, SA; Siemienczuk, D; Swan, HJ, 1982
)
0.56
"Minoxidil, a potent peripheral vasodilator, was used concomitantly with other antihypertensive drugs for severe hypertension in three children for 47 to 158 weeks at the dosage of 40 to 50 mg/day."( Rebound hypertension following minoxidil withdrawal.
Makker, SP; Moorthy, B, 1980
)
1.99
" The haemodynamic effects and pharmacokinetic profile of acute dosing with tolmesoxide, a new vasodilator antihypertensive agent are described."( The clinical pharmacology of vasodilator antihypertensive drugs.
Kelly, JG; McNay, JL; O'Boyle, C; O'Brien, ET; O'Malley, K, 1980
)
0.26
" A third group of 5 dogs received glyburide alone in the same dosing regimen as in the combination group."( The pharmacologic basis of the cardiovascular toxicity of minoxidil in the dog.
DuCharme, DW; Higgins, MJ; Mesfin, GM; Robinson, FG; Zhong, WZ,
)
0.38
" Scalp hair was collected by shaving and vacuuming the dosed area at baseline and at 4-week intervals."( The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque.
Brunden, MN; Diani, AR; Shull, KL; Zaya, MJ, 1995
)
0.52
" M-mode echocardiography was performed under two-dimensional echocardiography guidance on three occasions the day before treatment, immediately before dosing and 1, 3 and 24 h after dosing."( Echocardiography, a non-invasive method for the investigation of heart morphology and function in laboratory dogs: 2. Effects of minoxidil and quinidine on the left ventricle function.
Hanton, G; Lodola, A, 1998
)
0.51
" The concentration of minoxidil required for 50% control growth at 7 days extrapolated from the dose-response curve was 600 micrograms/ml."( The effect of minoxidil on keratocyte proliferation in cell culture.
Alvi, NP; Chandler, JW; Dave, Y; Fiscella, R; McLeod, SD; Zhou, L, 1998
)
0.98
"Pharmacokinetic analysis suggests a longer dosage interval may be appropriate in patients with hepatic impairment."( Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998
)
0.62
" Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years."( Management of androgenetic alopecia.
Camacho-Martinez, F; Dawber, R; Tosti, A, 1999
)
0.3
"Three kinds of topical dosage forms of minoxidil (MXD), namely vesicles, double emulsions, and an inclusion complex with hydoxypropyl-beta-cyclodextrin (HP-beta-CD), were prepared."( Minoxidil-containing dosage forms: skin retention and after-rinsing hair-growth promotion.
Kim, JC; Lee, MH; Rang, MJ,
)
1.84
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Blood pressure and ECG data were simultaneously acquired from male dogs using a non-invasive and an invasive implanted telemetry system for 2 hours predose and 24 hours post dosing with vehicle (n=5), minoxidil at 1 mg/kg (n=4) and L-NAME at 10 mg/kg (n=5) on separate test days."( Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs.
McMahon, N; Milliken, P; Patel, B; Ward, G, 2012
)
0.57
"Statistically significant reductions in blood pressure and pulse pressure and increases in heart rate, with associated ECG interval changes were apparent following dosing with minoxidil using both methods."( Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs.
McMahon, N; Milliken, P; Patel, B; Ward, G, 2012
)
0.57
"The objective of the present work is to develop stability indicating high-performance liquid chromatographic method for the simultaneous determination of aminexil and minoxidil in pharmaceutical dosage form."( Stability indicating RP-HPLC method development and validation for the simultaneous determination of aminexil and minoxidil in pharmaceutical dosage form.
Sahithi, M; Siddiraju, S, 2015
)
0.82
" As such, we hypothesized that increasing the dosage of topical minoxidil to low metabolizers would increase the number of responders without increasing the incidence of adverse events."( Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil.
Goren, A; Kovacevic, M; McCoy, J; Shapiro, J,
)
1.81
"The clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans."( Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
Beal, K; Disa, JJ; Dusza, SW; Freites-Martinez, A; Freret, ME; Friedman, DN; Kukoyi, O; Lacouture, ME; Mechalakos, JG; Phillips, GS; Tinkle, CL; Trelles, S; Unger, RH; Wexler, LH; Wolden, SL, 2020
)
0.77
" Larger randomized comparative studies including standardized objective measurements should be done in order to clarify the best treatment protocol, including dosage and treatment duration."( Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Fabbrocini, G; Ocampo-Candiani, J; Ocampo-Garza, SS; Ruggiero, A; Villani, A, 2021
)
0.97
" The conventional topical dosage forms available in the market falls short in effectively managing alopecia."( Potential of nanoparticulate based delivery systems for effective management of alopecia.
Handa, M; Kesharwani, P; Mishra, P; Shukla, R; Singh, V; Ujjwal, RR, 2021
)
0.62
" In animal tests, compared with topical administration of minoxidil, the drug-free microneedle patches can more significantly promote hair regeneration within 7 days with lower dosing frequency."( A Drug-Free, Hair Follicle Cycling Regulatable, Separable, Antibacterial Microneedle Patch for Hair Regeneration Therapy.
Chen, X; Kong, M; Li, H; Qin, D; Qiu, K; Shi, Y; Yu, M; Zhang, W; Zhao, J, 2022
)
0.97
" Further large-scale studies are warranted to determine the efficacy and optimum dosage of systemic minoxidil for alopecia in the pediatric population."( Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.
John, JM; Sinclair, RD, 2023
)
1.54
"Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders."( Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study.
Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022
)
1.2
"Oral minoxidil has been used in various non-scarring and scarring alopecia at a lower dosage with less side effects and with promising results."( Comprehensive review of oral minoxidil in alopecia.
Modha, JD; Pathania, YS, 2022
)
1.53
" Although successful encapsulation of MIN has been observed in these nanocarriers, there is still scarce data regarding their loading in a final dosage form."( Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil.
Ahmed, N; Saleem, K; Siddiqui, B; Taqi, MM; Ur Rehman, A, 2022
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
dialkylarylamine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.15850.003245.467312,589.2998AID2517
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.59730.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency70.79460.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.78780.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID743255
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
cytochrome P450 2D6Homo sapiens (human)Potency7.76190.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency11.22020.794321.275750.1187AID624246
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency8.91250.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency0.07940.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.00810.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency1.41250.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency1.58490.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.25120.891312.067628.1838AID1487
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.89131.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency3.98111.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)422.66670.11007.190310.0000AID1443980; AID1449628; AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (58)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (198)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID513626Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID47799Effective dose in cat was determined1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
The antihypertensive and positive inotropic diterpene forskolin: effects of structural modifications on its activity.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID513632Induction of autophagy in human SK-N-MC cells assessed as increase in LC3-2 level at 3 uM after 24 hrs by immunoblotting analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID454536Hair growth stimulatory activity in bal stump-tailed monkey model2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Thyroid receptor agonists for the treatment of androgenetic alopecia.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID181983Increase in diastolic blood pressure for 6 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID513629Cytotoxicity against human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID194078Difference in systolic blood pressure observed prior to the first application and 2 hr after the fifth application at 5 mg/kg, po daily for 5 days to spontaneously hypertensive rats (SHR)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
The antihypertensive and positive inotropic diterpene forskolin: effects of structural modifications on its activity.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID513635Induction of autophagy in Atg positive human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID181969Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID454515Hair growth stimulatory activity in C3H/HeN mouse treated 5 days a week topically to shaved lower back twice daily for 4 weeks2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Thyroid receptor agonists for the treatment of androgenetic alopecia.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1281296Induction of cell differentiation in human HL60 at 10 uM after 3 days by leishmans staining based microscopic analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID181971Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID181977Increase in diastolic blood pressure for 1 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID188870Maximum percentage reduction in mean blood pressure in metacorticoid (DOCA) hypertensive rats at a standard oral dose of 10 mg/kg1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID47796Effective dose for lowering blood pressure in anesthetized cat when administered intravenously1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Cardiovascular effects of new water-soluble derivatives of forskolin.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID513627Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1281300Induction of cell differentiation in human HL60 cells at 10 uM co-administered with DAF measured after 3 days by NBT/MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID74441Positive ionotropic activity (0.1x10E 6 g/mL) was determined in guinea pig; no significant activity1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
The antihypertensive and positive inotropic diterpene forskolin: effects of structural modifications on its activity.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID181973Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID174572Difference in systolic blood pressure of SH rats observed prior to the first application and 2 hr after the fifth application at the oral dose of 5 mg/kg was expressed as Delta BP1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-py rim ido [6,1-a]isoquinolin-4-ones.
AID1281295Induction of cell differentiation in human HL60 cells at 10 uM co-administered with MDA measured after 3 days by NBT/MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID181967Increase in diastolic blood pressure for 0.03 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID181981Increase in diastolic blood pressure for 3 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1281289Induction of cell differentiation in human HL60 cells by NBT/MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID188735Maximum percentage reduction in mean blood pressure and heart rate in metacorticoid (DOCA) hypertensive rats at a standard oral dose of 10 mg/kg1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1903742Neuroprotective activity against paclitaxel-induced neurotoxicity in mouse primary DRG neuron assessed as induction of neurite outgrowth at 1000 nM relative to control2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID47801Dose estimated to produce 25 mm Hg fall in mean systemic blood pressure of anesthetized cat at 10 min after administration1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-py rim ido [6,1-a]isoquinolin-4-ones.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID181979Increase in diastolic blood pressure for 1.0 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID181975Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID513628Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID513633Induction of autophagy in Atg deficient mouse MFF expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID652178Confirmed Agonists of Novel Allosteric Modulators of the M1 Muscarinic Receptor2013Molecules (Basel, Switzerland), Jan-08, Volume: 18, Issue:1
Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,735)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990636 (36.66)18.7374
1990's290 (16.71)18.2507
2000's218 (12.56)29.6817
2010's313 (18.04)24.3611
2020's278 (16.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials244 (12.95%)5.53%
Reviews303 (16.08%)6.00%
Case Studies243 (12.90%)4.05%
Observational3 (0.16%)0.25%
Other1,091 (57.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (62)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women [NCT03488108]Phase 1/Phase 220 participants (Actual)Interventional2017-01-23Completed
A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients [NCT05417308]Early Phase 150 participants (Anticipated)Interventional2023-03-01Recruiting
Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex [NCT01319370]Phase 270 participants (Actual)Interventional2010-11-30Completed
Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia: A Preliminary, Randomized, Double-Blind Clinical Trial [NCT05681897]30 participants (Anticipated)Interventional2023-02-28Recruiting
Randomised, Crossover Bioavailability Clinical Trial of Oral Minoxidil 1 MG, After Single and Multiple Dose Administration to Healthy Volunteers Under Fasting Conditions. [NCT06015516]Phase 114 participants (Anticipated)Interventional2024-02-29Not yet recruiting
The Safety and Efficacy of Fractional Ablative 10, 600nm CO2 Laser-assisted Treatments for Male Pattern Hair Loss: a Randomized Cohort Study Comparing Stand-alone Laser Treatment, Laser Assisted Drug Delivery of Minoxidil 2% Solution , and Laser Assisted [NCT03852992]Phase 20 participants (Actual)Interventional2022-09-30Withdrawn(stopped due to Study was closed with IRB on 10/22/22)
Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial [NCT03535233]Phase 440 participants (Actual)Interventional2016-03-31Completed
Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement : A Randomized, Double-blind, Placebo-controlled Study [NCT02283645]Phase 464 participants (Anticipated)Interventional2015-01-31Not yet recruiting
A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia [NCT02280603]Phase 1/Phase 260 participants (Actual)Interventional2014-01-31Completed
Minoxidil Response Testing in Females With Female Pattern Hair Loss [NCT02206802]300 participants (Anticipated)Observational2014-07-31Completed
Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men [NCT05989165]Phase 336 participants (Actual)Interventional2023-06-01Completed
Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil [NCT01309191]14 participants (Actual)Interventional2011-04-30Completed
[NCT01325337]Phase 2307 participants (Actual)Interventional2011-06-30Completed
Topical 5% Minoxidil Versus 0.2%Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure: a Randomized Controlled Trial [NCT03528772]62 participants (Actual)Interventional2018-05-10Completed
A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss [NCT03351322]Phase 267 participants (Actual)Interventional2018-05-23Completed
Phase I Study of Safety and Pharmacokinetics of Once-Daily Topical Solution in Male Subjects With Androgenetic Alopecia [NCT05864885]Phase 114 participants (Anticipated)Interventional2023-06-09Not yet recruiting
Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil [NCT02486848]0 participants (Actual)Interventional2016-06-30Withdrawn
Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia- Pilot Study [NCT02154503]Phase 120 participants (Anticipated)Interventional2014-04-30Recruiting
International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia [NCT05888922]Phase 3520 participants (Anticipated)Interventional2024-03-31Not yet recruiting
Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows [NCT05790941]Early Phase 112 participants (Anticipated)Interventional2023-03-11Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia [NCT05990400]Phase 2/Phase 340 participants (Anticipated)Interventional2023-05-01Recruiting
Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men [NCT04209803]Phase 4100 participants (Anticipated)Interventional2018-12-01Recruiting
Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia [NCT04293822]Phase 460 participants (Anticipated)Interventional2020-06-30Not yet recruiting
Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study [NCT01391156]Phase 340 participants (Actual)Interventional2011-03-31Completed
Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Mod [NCT00958750]Phase 3113 participants (Actual)Interventional2008-06-30Completed
Minoxidil in Treatment of Androgenetic Alopecia [NCT04090801]Phase 460 participants (Actual)Interventional2015-05-30Completed
A Pilot Study of Oral Minoxidil for the Treatment of Persistent Hair Loss in Pediatric, Adolescent, and Young Adult Cancer Survivors [NCT05778825]Phase 260 participants (Anticipated)Interventional2023-03-10Recruiting
A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males [NCT00151515]Phase 3352 participants (Actual)Interventional2003-10-31Completed
Efficacy of Therapy With the Anti-androgen Spironolactone Compared to Topical Minoxidil in Female Pattern Hair Loss [NCT00175617]Phase 240 participants (Anticipated)Interventional2005-09-30Completed
Minoxidil Response Testing in Males With Androgenetic Alopecia [NCT02198261]300 participants (Anticipated)Observational2014-07-31Completed
Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2) [NCT01900041]Phase 274 participants (Actual)Interventional2012-04-30Completed
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II) [NCT02460497]61 participants (Actual)Interventional2015-05-27Completed
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV) [NCT02460289]63 participants (Actual)Interventional2015-05-19Completed
Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination Compared to Topical 5% Minoxidil Monotherapy in Male Androgenetic Alopecia [NCT06043349]Phase 436 participants (Actual)Interventional2023-06-01Active, not recruiting
A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) [NCT01226459]Phase 3404 participants (Actual)Interventional2010-09-30Completed
A Phase I/II Clinical Study of Topical Minoxidil in Acne Vulgaris [NCT06108193]Phase 1/Phase 226 participants (Anticipated)Interventional2023-07-11Recruiting
[NCT01325350]Phase 2306 participants (Actual)Interventional2011-06-30Completed
Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study [NCT01672307]Phase 440 participants (Actual)Interventional2012-09-30Completed
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial [NCT05296863]Phase 337 participants (Actual)Interventional2021-10-11Completed
A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) [NCT01145625]Phase 3322 participants (Actual)Interventional2010-06-30Completed
Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement : A Randomized, Double-blind, Placebo-controlled Study [NCT02275832]Phase 448 participants (Actual)Interventional2014-11-30Completed
The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia [NCT02483195]Phase 40 participants (Actual)Interventional2016-08-31Withdrawn(stopped due to PI indicating she was withdrawing her study submission due to lack of funding as of 6/20/2016)
A Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension With Direct Vasodilators, Minoxidil and Hydralazine [NCT00607477]2 participants (Actual)Interventional2008-01-31Terminated(stopped due to Study has been terminated due to poor accrual.)
A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer [NCT05272462]Phase 234 participants (Anticipated)Interventional2021-12-13Recruiting
The Role of Cetirizine in Androgenetic Alopecia in Females [NCT04481412]Phase 2/Phase 366 participants (Actual)Interventional2020-07-25Completed
Minoxidil 1% for Eyebrow Enhancement: A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study [NCT01924000]Phase 440 participants (Actual)Interventional2013-12-31Completed
A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) [NCT01643629]Phase 1/Phase 220 participants (Anticipated)Interventional2012-01-31Active, not recruiting
An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA [NCT01650272]Phase 1/Phase 220 participants (Anticipated)Interventional2012-06-30Recruiting
BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA [NCT01655108]Phase 360 participants (Anticipated)Interventional2012-03-31Active, not recruiting
The Efficacy of Minoxidil in Children With Williams-Beuren Syndrome: a Randomized Clinical Trial. [NCT00876200]Phase 221 participants (Actual)Interventional2009-03-31Completed
Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata [NCT05587257]60 participants (Anticipated)Interventional2023-01-01Not yet recruiting
Hair Regeneration in Androgenetic Alopecia Using Secretome of Adipose-derived Stem Cells (ADSC) and Minoxidil: A Comparative Study of Three Groups [NCT06066827]60 participants (Actual)Interventional2023-08-14Active, not recruiting
A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men [NCT05636904]Phase 1/Phase 2120 participants (Actual)Interventional2022-12-05Active, not recruiting
Comparative Study Between the Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in the Treatment of Male Androgenic Alopecia [NCT05369481]50 participants (Anticipated)Interventional2022-03-01Recruiting
National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia. [NCT04594018]Phase 3190 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study [NCT03753113]Phase 324 participants (Actual)Interventional2018-11-28Completed
A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks [NCT04721548]Phase 3336 participants (Anticipated)Interventional2023-03-02Recruiting
A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androg [NCT02279823]Phase 295 participants (Actual)Interventional2014-10-31Completed
A Randomized Controlled Trial of the Efficacy and Safety of 1565nm Non-ablative Fractional Laser on Treating Androgenic Alopecia [NCT05827991]75 participants (Anticipated)Interventional2022-03-01Recruiting
An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia [NCT03831334]Early Phase 125 participants (Anticipated)Interventional2019-04-09Recruiting
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study [NCT04207931]Phase 4250 participants (Anticipated)Interventional2018-04-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00876200 (1) [back to overview]Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography
NCT01145625 (3) [back to overview]Target Area Hair Count (TAHC)
NCT01145625 (3) [back to overview]Target Area Hair Count (TAHC)
NCT01145625 (3) [back to overview]Target Area Hair Count (TAHC)
NCT01226459 (3) [back to overview]Subject Assessment of Scalp Coverage
NCT01226459 (3) [back to overview]Target Area Hair Count
NCT01226459 (3) [back to overview]Target Area Hair Count
NCT01325337 (6) [back to overview]Change From Baseline in Target Area Hair Count (TAHC)
NCT01325337 (6) [back to overview]Change From Baseline in Target Area Hair Darkness (TAHD)
NCT01325337 (6) [back to overview]Change From Baseline in Target Area Hair Width (TAHW)
NCT01325337 (6) [back to overview]Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score
NCT01325337 (6) [back to overview]Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score
NCT01325337 (6) [back to overview]Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score
NCT01325350 (6) [back to overview]Change From Baseline in Target Area Hair Count (TAHC)
NCT01325350 (6) [back to overview]Change From Baseline in Target Area Hair Darkness (TAHD)
NCT01325350 (6) [back to overview]Change From Baseline in Target Area Hair Width (TAHW)
NCT01325350 (6) [back to overview]Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score
NCT01325350 (6) [back to overview]Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score
NCT01325350 (6) [back to overview]Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score
NCT02460289 (5) [back to overview]Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12
NCT02460289 (5) [back to overview]Mean Change From Baseline in Shed Hair Count
NCT02460289 (5) [back to overview]Number of Participants With Adverse Events (AEs)
NCT02460289 (5) [back to overview]Change From Baseline in Participant Rating at Week 12
NCT02460289 (5) [back to overview]Number of Participant in Each Response Category Based on Subject Satisfaction Questionnaire
NCT02460497 (5) [back to overview]Change From Baseline in Investigator's Rating of Global Photographs at Week 12
NCT02460497 (5) [back to overview]Change From Baseline in Participant Rating at Week 12
NCT02460497 (5) [back to overview]Number of Participants in Each Response Category Based on Subject Satisfaction Questionnaire
NCT02460497 (5) [back to overview]Mean Change From Baseline in Shed Hair Count
NCT02460497 (5) [back to overview]Number of Participants With Adverse Events (AEs)
NCT03488108 (6) [back to overview]Change in Terminal Hair Density
NCT03488108 (6) [back to overview]Change in Vellus Hair Density
NCT03488108 (6) [back to overview]Adverse Event of Redness on Scalp
NCT03488108 (6) [back to overview]Adverse Event of Swelling on Scalp
NCT03488108 (6) [back to overview]Change in Cumulative Thickness
NCT03488108 (6) [back to overview]Change in Hair Count
NCT03753113 (3) [back to overview]Patients Self - Assessment Questionnaire
NCT03753113 (3) [back to overview]Adverse Events
NCT03753113 (3) [back to overview]Change in Hair Diameter

Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography

(NCT00876200)
Timeframe: 12 months

Interventionmm (Mean)
Minoxidil0.028
Placebo0.012

[back to top]

Target Area Hair Count (TAHC)

Number of hairs in the area being examined as measured by macrophotography (NCT01145625)
Timeframe: Baseline to Week 12

,
Interventionhairs per centimeter squared (Mean)
BaselineWeek 12Change from Baseline to Week 12
2% MTS167.3190.722.5
5% MTF169.7191.824.9

[back to top]

Target Area Hair Count (TAHC)

Number of hairs in the area being examined as measured by macrophotography. (NCT01145625)
Timeframe: Baseline to Week 24

,
Interventionhairs per centimeter squared (Mean)
BaselineWeek 24Change from Baseline to Week 24
2% MTS167.3192.823.8
5% MTF169.7194.423.7

[back to top]

Target Area Hair Count (TAHC)

Number of hairs in the area being examined as measured by macrophotography. (NCT01145625)
Timeframe: Baseline to Week 52

,
Interventionhairs per centimeter squared (Mean)
BaselineWeek 52Change from Baseline to Week 52
2% MTS167.3189.119.4
5% MTF169.7186.918.1

[back to top]

Subject Assessment of Scalp Coverage

Subject assessment of scalp coverage at Week 24 was measured as change from Baseline on a 7-point scale where 0 meant no perceived change in scalp coverage, +1 to +3 indicated progressively increased levels of scalp coverage, and -1 to -3 indicated progressively decreased levels. (NCT01226459)
Timeframe: Week 24

Interventionscores on a scale (Mean)
Vehicle Foam0.06
Minoxidil Foam0.74

[back to top]

Target Area Hair Count

Number of hairs in the area being examined as measured by macrophotography. (NCT01226459)
Timeframe: Baseline to Week 12

,
Interventionhairs per centimeter squared (Mean)
BaselineWeek 12Change from Baseline to Week 12
Minoxidil Foam158.6178.116.4
Vehicle Foam152.7163.35.4

[back to top]

Target Area Hair Count

Number of hairs in the area being examined as measured by macrophotography. (NCT01226459)
Timeframe: Baseline to Week 24

,
Interventionhairs per centimeter squared (Mean)
BaselineWeek 24Change from Baseline to Week 24
Minoxidil Foam158.6175.713.5
Vehicle Foam152.7162.24.0

[back to top]

Change From Baseline in Target Area Hair Count (TAHC)

TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). (NCT01325337)
Timeframe: Baseline, Month 6

,,,,
Interventionterminal hairs/cm^2 (Mean)
BaselineChange from Baseline at Month 6
Bimatoprost Formulation A135.013.1
Bimatoprost Formulation B145.76.1
Bimatoprost Formulation C151.56.3
Minoxidil 5% Solution132.721.9
Vehicle to Bimatoprost143.74.1

[back to top]

Change From Baseline in Target Area Hair Darkness (TAHD)

Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns in width) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs). (NCT01325337)
Timeframe: Baseline, Month 6

,,,,
InterventionIntensity units (Mean)
BaselineChange from Baseline at Month 6
Bimatoprost Formulation A106.881.19
Bimatoprost Formulation B103.852.92
Bimatoprost Formulation C100.814.04
Minoxidil 5% Solution99.573.40
Vehicle to Bimatoprost104.030.65

[back to top]

Change From Baseline in Target Area Hair Width (TAHW)

Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns in width) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). (NCT01325337)
Timeframe: Baseline, Month 6

,,,,
Interventionmm/cm^2 (Mean)
BaselineChange from Baseline at Month 6
Bimatoprost Formulation A7.830.76
Bimatoprost Formulation B8.340.25
Bimatoprost Formulation C8.590.12
Minoxidil 5% Solution7.821.29
Vehicle to Bimatoprost8.350.13

[back to top]

Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score

"At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: Compared with the baseline image, the amount of the subject's hair has?: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented." (NCT01325337)
Timeframe: Baseline, Month 6

,,,,
InterventionPercentage of participants (Number)
Greatly IncreasedModerately IncreasedSlightly IncreasedRemained the SameSlightly DecreasedModerately DecreasedGreatly Decreased
Bimatoprost Formulation A0.03.517.571.97.00.00.0
Bimatoprost Formulation B0.01.810.773.214.30.00.0
Bimatoprost Formulation C0.00.08.674.117.20.00.0
Minoxidil 5% Solution0.05.239.750.03.41.70.0
Vehicle to Bimatoprost0.00.08.975.016.10.00.0

[back to top]

Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score

"The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: Since the start of the study, the amount of the subject's hair has?: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented." (NCT01325337)
Timeframe: Baseline, Month 6

,,,,
InterventionPercentage of participants (Number)
Greatly IncreasedModerately IncreasedSlightly IncreasedRemained the SameSlightly DecreasedModerately DecreasedGreatly Decreased
Bimatoprost Formulation A0.012.129.348.310.30.00.0
Bimatoprost Formulation B5.16.828.855.93.40.00.0
Bimatoprost Formulation C0.04.923.063.98.20.00.0
Minoxidil 5% Solution8.624.115.544.86.90.00.0
Vehicle to Bimatoprost0.06.925.963.83.40.00.0

[back to top]

Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score

"The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: Since the start of the study, the amount of my hair has?: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented." (NCT01325337)
Timeframe: Baseline, Month 6

,,,,
InterventionPercentage of participants (Number)
Greatly IncreasedModerately IncreasedSlightly IncreasedRemained the SameSlightly DecreasedModerately DecreasedGreatly Decreased
Bimatoprost Formulation A0.08.631.043.113.83.40.0
Bimatoprost Formulation B1.711.923.740.715.35.11.7
Bimatoprost Formulation C0.011.716.741.720.06.73.3
Minoxidil 5% Solution5.227.634.522.48.61.70.0
Vehicle to Bimatoprost1.76.919.051.719.01.70.0

[back to top]

Change From Baseline in Target Area Hair Count (TAHC)

TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). A negative change from Baseline indicated worsening (decrease in the number of terminal hairs). (NCT01325350)
Timeframe: Baseline, Month 6

,,,,
Interventionterminal hairs/cm^2 (Mean)
BaselineChange from Baseline at Month 6
Bimatoprost Formulation A153.1-0.4
Bimatoprost Formulation B161.1-3.5
Bimatoprost Formulation C145.24.3
Minoxidil 2% Solution156.313.6
Vehicle to Bimatoprost163.01.1

[back to top]

Change From Baseline in Target Area Hair Darkness (TAHD)

Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs). (NCT01325350)
Timeframe: Baseline, Month 6

,,,,
InterventionIntensity units (Mean)
BaselineChange from Baseline at Month 6
Bimatoprost Formulation A95.632.94
Bimatoprost Formulation B100.124.22
Bimatoprost Formulation C92.762.11
Minoxidil 2% Solution93.072.12
Vehicle to Bimatoprost96.902.07

[back to top]

Change From Baseline in Target Area Hair Width (TAHW)

Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). A negative change from Baseline indicated worsening (decrease in the diameter of terminal hairs). (NCT01325350)
Timeframe: Baseline, Month 6

,,,,
Interventionmm/cm^2 (Mean)
BaselineChange from Baseline from Month 6
Bimatoprost Formulation A8.920.13
Bimatoprost Formulation B9.64-0.19
Bimatoprost Formulation C8.860.30
Minoxidil 2% Solution9.760.87
Vehicle to Bimatoprost10.130.07

[back to top]

Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score

"At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: Compared with the baseline image, the amount of the subject's hair has?: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented." (NCT01325350)
Timeframe: Baseline, Month 6

,,,,
InterventionPercentage of participants (Number)
Greatly IncreasedModerately IncreasedSlightly IncreasedRemained the SameSlightly DecreasedModerately DecreasedGreatly Decreased
Bimatoprost Formulation A0.01.80.087.310.90.00.0
Bimatoprost Formulation B0.00.06.881.411.90.00.0
Bimatoprost Formulation C0.02.16.381.310.40.00.0
Minoxidil 2% Solution0.00.017.079.21.91.90.0
Vehicle to Bimatoprost0.01.66.688.53.30.00.0

[back to top]

Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score

"The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: Since the start of the study, the amount of the subject's hair has?: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented." (NCT01325350)
Timeframe: Baseline, Month 6

,,,,
InterventionPercentage of participants (Number)
Greatly IncreasedModerately IncreasedSlightly IncreasedRemained the SameSlightly DecreasedModerately DecreasedGreatly Decreased
Bimatoprost Formulation A5.212.124.139.715.53.40.0
Bimatoprost Formulation B3.310.035.040.010.01.70.0
Bimatoprost Formulation C7.411.125.951.93.70.00.0
Minoxidil 2% Solution1.816.137.541.13.60.00.0
Vehicle to Bimatoprost1.614.823.054.16.60.00.0

[back to top]

Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score

"The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: Since the start of the study, the amount of my hair has?: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented." (NCT01325350)
Timeframe: Baseline, Month 6

,,,,
InterventionPercentage of participants (Number)
Greatly IncreasedModerately IncreasedSlightly IncreasedRemained the SameSlightly DecreasedModerately DecreasedGreatly Decreased
Bimatoprost Formulation A3.417.234.520.719.01.73.4
Bimatoprost Formulation B3.320.021.733.311.78.31.7
Bimatoprost Formulation C9.316.716.738.913.05.60.0
Minoxidil 2% Solution7.128.635.719.65.41.81.8
Vehicle to Bimatoprost3.318.024.629.513.18.23.3

[back to top]

Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12

The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. Investigator global photograph rating were assessed using 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree. (NCT02460289)
Timeframe: At Week 12

InterventionScore on a scale (Mean)
Hair ThinningHair GrowthImpression of scalp hair coverageOverall perception of treatment benefit
Minoxidil 5% Foam and Botanical Hair Solution for Men5.05.15.15.1

[back to top]

Mean Change From Baseline in Shed Hair Count

Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at Week 12. (NCT02460289)
Timeframe: At Week 12

InterventionShed Hair Count (Mean)
Minoxidil 5% Foam and Botanical Hair Solution for Men14.1

[back to top]

Number of Participants With Adverse Events (AEs)

AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus, any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE. (NCT02460289)
Timeframe: From start of study up to Week 12

InterventionParticipants (Count of Participants)
Minoxidil 5% Foam and Botanical Hair Solution for Men4

[back to top]

Change From Baseline in Participant Rating at Week 12

Participants rated the parameters like appearance of hair, growth of hair, satisfaction with hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree. (NCT02460289)
Timeframe: At Week 12

InterventionScore on a scale (Mean)
Appearance of hairGrowth of hairSatisfaction with hairline at the front of the headSatisfaction with hair on the top of the headSatisfaction with hair overall as an overall improvement
Minoxidil 5% Foam and Botanical Hair Solution for Men5.45.34.95.05.2

[back to top]

Number of Participant in Each Response Category Based on Subject Satisfaction Questionnaire

Participant's satisfaction questionnaire was used to specifically collect the participants' feedback on the treatment regimen, the level of satisfaction and future usage. Participants were asked to complete a cosmetic acceptability questionnaire. This 10 item questionnaire had a 5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree). (NCT02460289)
Timeframe: At Week 4,6 and 12

InterventionParticipants (Count of Participants)
Satisfaction with appearance of hair (At Week 4)72278216Satisfaction with appearance of hair (At Week 6)72278216Satisfaction with appearance of hair (At Week 12)72278216Satisfaction with growth of hair (At Week 4)72278216Satisfaction with growth of hair (At Week 6)72278216Satisfaction with growth of hair (At Week 12)72278216Satisfaction with hairline at the front of the head (At Week 4)72278216Satisfaction with hairline at the front of the head (At Week 6)72278216Satisfaction with hairline at the front of the head (At Week 12)72278216Satisfaction with hair on the top of the head (At Week 4)72278216Satisfaction with hair on the top of the head (At Week 6)72278216Satisfaction with hair on the top of the head (At Week 12)72278216Satisfaction with hair overall as an overall improvement from the baseline (At Week 4)72278216Satisfaction with hair overall as an overall improvement from the baseline (At Week 6)72278216Satisfaction with hair overall as an overall improvement from the baseline (At Week 12)72278216
DisagreeNeutralAgree
Minoxidil 5% Foam and Botanical Hair Solution for Men27
Minoxidil 5% Foam and Botanical Hair Solution for Men42
Minoxidil 5% Foam and Botanical Hair Solution for Men44
Minoxidil 5% Foam and Botanical Hair Solution for Men4
Minoxidil 5% Foam and Botanical Hair Solution for Men12
Minoxidil 5% Foam and Botanical Hair Solution for Men18
Minoxidil 5% Foam and Botanical Hair Solution for Men40
Minoxidil 5% Foam and Botanical Hair Solution for Men26
Minoxidil 5% Foam and Botanical Hair Solution for Men10
Minoxidil 5% Foam and Botanical Hair Solution for Men20
Minoxidil 5% Foam and Botanical Hair Solution for Men8
Minoxidil 5% Foam and Botanical Hair Solution for Men14
Minoxidil 5% Foam and Botanical Hair Solution for Men21
Minoxidil 5% Foam and Botanical Hair Solution for Men16
Minoxidil 5% Foam and Botanical Hair Solution for Men19
Minoxidil 5% Foam and Botanical Hair Solution for Men36
Minoxidil 5% Foam and Botanical Hair Solution for Men7
Minoxidil 5% Foam and Botanical Hair Solution for Men13
Minoxidil 5% Foam and Botanical Hair Solution for Men37
Minoxidil 5% Foam and Botanical Hair Solution for Men22
Minoxidil 5% Foam and Botanical Hair Solution for Men34
Minoxidil 5% Foam and Botanical Hair Solution for Men5
Minoxidil 5% Foam and Botanical Hair Solution for Men17
Minoxidil 5% Foam and Botanical Hair Solution for Men39
Minoxidil 5% Foam and Botanical Hair Solution for Men6
Minoxidil 5% Foam and Botanical Hair Solution for Men11

[back to top]

Change From Baseline in Investigator's Rating of Global Photographs at Week 12

The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. The score on the scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree. (NCT02460497)
Timeframe: At Week 12

InterventionScore on a scale (Mean)
Hair ThinningHair GrowthImpression of scalp hair coverageOverall perception of treatment benefit
Minoxidil 5% Foam and Botanical Hair Solution4.94.94.85.0

[back to top]

Change From Baseline in Participant Rating at Week 12

Participants rated the parameters like appearance of hair, growth of hair, satisfaction with Hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. The scores on the scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree. (NCT02460497)
Timeframe: At Week 12

InterventionScore on a scale (Mean)
Appearance of hairGrowth of hairSatisfaction with hairline at the front of the headSatisfaction with hair on the top of the headSatisfaction with hair overall as an overall improvement from the baseline
Minoxidil 5% Foam and Botanical Hair Solution5.65.45.15.15.5

[back to top]

Number of Participants in Each Response Category Based on Subject Satisfaction Questionnaire

Participant satisfaction with the treatment experience data was collected via a written questionnaire This questionnaire composed of 5-point Likert scale questions, as well as free-text responses. Participants were asked to determine overall satisfaction with the treatment. The choices were: 1-2 = Agree; 4-5 = Disagree; 3 = Neutral. (NCT02460497)
Timeframe: At Week 4, 6 and 12

InterventionParticipants (Count of Participants)
I have noticed an improvement in the appearance of my hair (At Week 4)72278212I have noticed an improvement in the appearance of my hair (At Week 6)72278212I have noticed an improvement in the appearance of my hair (At Week 12)72278212This Regimen provides thicker looking hair (At Week 4)72278212This Regimen provides thicker looking hair (At Week 6)72278212My hair looks fuller (At Week 4)72278212My hair looks fuller (At Week 6)72278212My hair looks noticeably fuller (At Week 12)72278212This Regimen provides healthier looking hair (At Week 4)72278212This Regimen provides healthier looking hair (At Week 6)72278212I am happy with the appearance of hair (At Week 4)72278212I am happy with the appearance of hair (At Week 6)72278212This Regimen improves my hair volume (At Week 4)72278212This Regimen improves my hair volume (At Week 6)72278212This Regimen improves my hair volume (At Week 12)72278212This Regimen improves my hair texture (At Week 4)72278212This Regimen improves my hair texture (At Week 6)72278212This Regimen improves my hair texture (At Week 12)72278212I have noticed an improvement in my hair quality (At Week 4)72278212I have noticed an improvement in my hair quality (At Week 6)72278212I have noticed an improvement in my hair quality (At Week 12)72278212My scalp feels better since beginning this Regimen (At Week 4)72278212My scalp feels better since beginning this Regimen (At Week 6)72278212My hair looks stronger (At Week 4)72278212My hair looks stronger (At Week 6)72278212My hair looks stronger (At Week 12)72278212I like the Regimen I used in this study (At Week 12)72278212I received compliments from friends and family members about my hair (At Week 12)72278212I would recommend this Regimen to others (At Week 12)72278212I feel younger (At Week 12)72278212I thought this Regimen did better than my previous hair thinning products (At Week 12)72278212I feel more attractive (At Week 12)72278212I feel more sociable (At Week 12)72278212I feel more confident (At Week 12)72278212I would purchase this Regimen (At Week 12)72278212My hair looks heathier (At Week 12)72278212
NeutralAgreeDisagree
Minoxidil 5% Foam and Botanical Hair Solution27
Minoxidil 5% Foam and Botanical Hair Solution13
Minoxidil 5% Foam and Botanical Hair Solution14
Minoxidil 5% Foam and Botanical Hair Solution37
Minoxidil 5% Foam and Botanical Hair Solution9
Minoxidil 5% Foam and Botanical Hair Solution45
Minoxidil 5% Foam and Botanical Hair Solution4
Minoxidil 5% Foam and Botanical Hair Solution5
Minoxidil 5% Foam and Botanical Hair Solution25
Minoxidil 5% Foam and Botanical Hair Solution38
Minoxidil 5% Foam and Botanical Hair Solution8
Minoxidil 5% Foam and Botanical Hair Solution24
Minoxidil 5% Foam and Botanical Hair Solution18
Minoxidil 5% Foam and Botanical Hair Solution43
Minoxidil 5% Foam and Botanical Hair Solution22
Minoxidil 5% Foam and Botanical Hair Solution17
Minoxidil 5% Foam and Botanical Hair Solution28
Minoxidil 5% Foam and Botanical Hair Solution36
Minoxidil 5% Foam and Botanical Hair Solution26
Minoxidil 5% Foam and Botanical Hair Solution12
Minoxidil 5% Foam and Botanical Hair Solution16
Minoxidil 5% Foam and Botanical Hair Solution35
Minoxidil 5% Foam and Botanical Hair Solution6
Minoxidil 5% Foam and Botanical Hair Solution41
Minoxidil 5% Foam and Botanical Hair Solution7
Minoxidil 5% Foam and Botanical Hair Solution21
Minoxidil 5% Foam and Botanical Hair Solution29
Minoxidil 5% Foam and Botanical Hair Solution42
Minoxidil 5% Foam and Botanical Hair Solution23
Minoxidil 5% Foam and Botanical Hair Solution10
Minoxidil 5% Foam and Botanical Hair Solution19
Minoxidil 5% Foam and Botanical Hair Solution33
Minoxidil 5% Foam and Botanical Hair Solution11
Minoxidil 5% Foam and Botanical Hair Solution15
Minoxidil 5% Foam and Botanical Hair Solution31
Minoxidil 5% Foam and Botanical Hair Solution40

[back to top]

Mean Change From Baseline in Shed Hair Count

Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at week 12. (NCT02460497)
Timeframe: At Week 12

InterventionShed Hair Count (Mean)
Minoxidil 5% Foam and Botanical Hair Solution4.9

[back to top]

Number of Participants With Adverse Events (AEs)

AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE. (NCT02460497)
Timeframe: From start of study drug administration up to Week 12

InterventionParticipants (Count of Participants)
Minoxidil 5% Foam and Botanical Hair Solution2

[back to top]

Change in Terminal Hair Density

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of Terminal hairs per cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma-0.7
Minoxidil Foam12.8

[back to top]

Change in Vellus Hair Density

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of vellus hairs per cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma25.7
Minoxidil Foam18.6

[back to top]

Adverse Event of Redness on Scalp

Total number of participants experiencing Redness on Scalp was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: after 12 weeks of treatment

InterventionParticipants (Count of Participants)
Platelet Rich Plasma0
Minoxidil Foam0

[back to top]

Adverse Event of Swelling on Scalp

Total number of participants experiencing swelling on scalp was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: after 12 weeks of treatment

InterventionParticipants (Count of Participants)
Platelet Rich Plasma0
Minoxidil Foam0

[back to top]

Change in Cumulative Thickness

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total sum of thickness of each hair was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma-3.5
Minoxidil Foam20.6

[back to top]

Change in Hair Count

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of hairs per 0.65 cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma7.7
Minoxidil Foam22.7

[back to top]

Patients Self - Assessment Questionnaire

Self-administered hair growth questionnaire, consisting of 4 questions in the patient's language on treatment efficacy and three questions on satisfaction with appearance. For differences between self-assessment questionnaires. This questionnaire following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very dissatisfied. Higher scores indicated a worse outcome. (NCT03753113)
Timeframe: through study completion

Interventionscore on a scale (Mean)
Treatment Group1.25
Control Group2.58

[back to top]

Adverse Events

Incidence of adverse events such as itching, redness, inflammation etc (NCT03753113)
Timeframe: baseline, 12, 24, and 36 weeks

,
InterventionParticipants (Count of Participants)
scalp itchingscalp drynessheadache
Control Group422
Treatment Group100

[back to top]

Change in Hair Diameter

Change in hair diameter over time as compared to Baseline. Hair diameter measured via a digital micrometer. (NCT03753113)
Timeframe: baseline, 12, 24, and 36 weeks

,
Interventionmicrometer (Mean)
Week 12Week 24Week 36
Control Group51.5851.1750.58
Treatment Group57.4260.9262.67

[back to top]